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1. INTRODUCTION 
 
 
1.1. Bladder anatomy and histology 
 
The adult bladder is located in the anterior pelvis and is enveloped by extraperitoneal fat and 
connective tissue. It is separated from the pubic symphysis by an anterior prevesical space known 
as the space of Retzius or retropubic space. The dome of the bladder is covered by peritoneum, and 
the bladder neck is fixed to neighbouring structures by reflections of the pelvic fascia and by true 
ligaments of the pelvis. The body of the bladder receives inferior support from the pelvic 
diaphragm in females or prostate in males and lateral support from the obturator internus and 
levator ani muscles. At its apex, the medial umbilical ligament, or the urachal remnant, courses 
along the anterior abdominal wall to the umbilicus (1).  
The renal pelvis, ureters, bladder, and urethra (except the terminal portion) are lined by a special 
form of transitional epithelium called urothelium. Urothelium is composed of five to six layers of 
cells with oval nuclei, often with linear nuclear grooves, and a surface layer consisting of large, 
flattened “umbrella cells” with abundant cytoplasm, that cover several underlying cells. The 
umbrella cells have a trilaminar asymmetric unit membrane and possess apical plaques composed 
of specific proteins called uroplakins. Toward the basal layer, the cells become smaller or more 
cylindrical (particularly in the contracted bladder), but they are capable of some flattening when 
the underlying wall is stretched.  This epithelium rests on a well-developed basement membrane, 
beneath which is a lamina propria. The lamina propria in the urinary bladder contains wisps of 
smooth muscle that form discontinuous muscularis mucosae. It is important to differentiate the 
muscularis mucosae from the deeper well-defined larger muscle bundles of the detrusor muscle 
(muscularis propria) since bladder cancers are staged on the basis of invasion of the latter. If urine 
flow is obstructed and intravesical pressures rise, the bladder musculature undergoes hypertrophy 
(2).  
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Several variants of the normal epithelial patterns may be encountered. Nests of urothelium or in-
budding of the surface epithelium may be found occasionally in the mucosa lamina propria; these 
are referred to as Brunn nests (2).  
 
 
1.2. Bladder embryology and development 
 
The human urinary bladder derives from the urogenital sinus, and it is initially continuous with 
the allantois. The upper and lower parts of the bladder develop separately and join together around 
the middle part of development. At this time the ureters move from the mesonephric ducts to the 
trigone (3). In male, the base of the bladder lies between the rectum and the pubic symphysis. It is 
superior to the prostate and separated from the rectum by the recto-vesical pouch. In females, the 
bladder sits inferior to the uterus and anterior to the vagina; thus, its maximum capacity is lower 
than in males. It is separated from the uterus by the vesico-uterine pouch. In infants and young 
children, the urinary bladder is in the abdomen even when empty (4). 
 
 
1.3. Bladder pathology 
 
The bladder is an organ that is prone to different diseases. An important part of all bladder 
pathology which constitutes an important source of clinical signs and symptoms are bladder 
inflammations. While bladder tumours are an important source of both morbidity and mortality (2). 
Bladder non-tumoral pathology extends from congenital anomalies (bladder diverticula, extrophy, 
vesicoureteral reflux, congenital fistulas, urachal cysts, etc), inflammations (acute and chronic 
cystitis, interstitial cystitis, malacoplakia, polypoid cystitis) and metaplastic lesions (cystitis 
glandularis, cystitis cystica, squamous metaplasia, nephrogenic metaplasia) (2).  
Bladder tumours can be either benign or malignant tumours. 
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1.3.1. Benign tumours 
 
Neoplasms of the bladder pose biologic and clinical challenges. Despite significant inroads into 
their origins and improved methods of diagnosis and treatment, they continue to exact a high toll 
in morbidity and mortality (5). 
Urothelial papilloma. It is an exophytic tumour composed of a delicate fibrovascular core covered 
by urothelium indistinguishable from that of the normal urothelium. The incidence is low, usually 
1-4%, with a male to female ratio from 1.9:1, and they tend to occur in younger patients. The lesion 
is characterized by discrete papillary fronds, with occasional branching, but without fusion. 
Cytokeratin 20 expression is identical to that of normal urothelium- in superficial umbrella cells 
only. Alteration of p53 is not seen (5).   
Inverted papilloma. A benign urothelial tumour that has an inverted growth pattern with normal 
to minimal cytologic atypia of the neoplastic cells. It comprises about 1% of urothelial neoplasms, 
being more 4-5-fold more frequent in male, with a pick frequency in 6th and 7th decade. Haematuria 
is the most common symptom. If located in the low bladder neck or the ureter it can produce also 
signs of obstruction. It appears as a smooth-surfaced pedunculated or sessile polypoid lesion, 
covered by histologically and cytologically normal epithelium with randomly scattered endophytic 
cords (5). 
 
 
1.3.2. Bladder cancer 
 
1.3.2.1. Epidemiology  
Urinary bladder cancer has become a common cancer globally, with an estimated 430,000 new 
cases diagnosed, and 165,000 bladder cancer deaths occurred worldwide in 2012, with 75% of the 
total burden occurring in men. It ranks as the ninth most frequently diagnosed cancer worldwide, 
with the highest incidence rates observed in men in Southern and Western Europe, as well as in 
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certain countries in North America and Western Asia. Incidence rates are consistently lower in 
women than men, although sex differences vary greatly between countries (6). The highest 
incidence rates in male were recorded in Southern Europe, particularly in Spain (age-standardized 
rate (ASR) =36.7 per 100,000) and Italy (ASR=33.2 per 100,000). Incidence rates are also very 
high among men in Nordic countries (e.g.: Denmark ASR=27.4 per 100,000). In females, the 
highest incidence rates are observed in Denmark (ASR=8.4 per 100,000), Norway (ASR=6.4 per 
100,000) and Switzerland (ASR=6.3 per 100,000) (6). 
The most common type of bladder cancer in developed countries is urothelial carcinoma, derived 
from the uroepithelium, which constitutes more than 90% of bladder cancer cases in the USA, 
France or Italy. However, in other regions (e.g. Eastern and Northern Europe, Africa, Asia) the 
relative frequency of urothelial carcinoma of the bladder is lower. In general, among all registries 
included into the 8th volume of "Cancer Incidence in Five Continents" urothelial carcinoma 
constitutes 84% of bladder cancer in males and 79% in females. Other types of bladder cancer, i.e. 
squamous cell carcinoma and adenocarcinoma have a much lower relative frequency. In all 
"Cancer Incidence in Five Continents" registries squamous cell carcinoma accounts for 1.1% and 
2.8% of all bladder cancers in men and women respectively. Adenocarcinoma of the bladder 
constitutes respectively 1.5% and 1.9% of all bladder tumours worldwide (5, 7). As with most of 
the carcinomas, its development seems to depend on a combination of genetic and environmental 
factors (8).  
 
 
1.3.2.2. Risk factors 
 
There are several known and potential risk factors for bladder cancer. Tobacco smoking and 
occupational exposure to aromatic amines are the most important among them (9). It is estimated 
that the risk of bladder cancer attributed to tobacco smoking is 66% for men and 30% for women. 
The risk of bladder cancer in smokers is a 2-6-fold that of non-smokers. The risk increases with 
increasing duration of smoking and with increasing intensity of smoking (number of cigarettes per 
day). The risk of bladder cancer goes down after stopping smoking, and 15 years after cessation 
tends to be approximately that of non-smokers (5).  
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The association of bladder cancer and occupational exposure was first observed in 1895 by Rehn, 
who reported high rates of bladder cancer among men employed in the aniline dye industry. It was 
estimated that contact with occupational carcinogens (benzidine, 2-naphtylamine, 1-naphtylamine, 
etc.) causes up to 25% of all bladder tumours (5).  
The bladder tumours are more frequent in industrial areas, where people are exposed to different 
environment pollutants (especially in those associated with petrochemicals) (10). In general, the 
prevalence of bladder tumours in developed countries is approximately 6-times higher compared 
with that in developing countries (5). 
Several epidemiological studies indicate that chronic abuse of analgesics containing phenacetin 
greatly enhance the risk of developing urothelial cancer of renal pelvis, ureter and bladder. The 
relative risk has been estimated to be 2.4 to more than 6. Other medicinal drugs like clornaphazine 
and cyclophosphamide, are associated with the development of bladder cancer (5). 
Another important factor in the pathogenesis of bladder carcinoma is infestation with Schistosoma 
haematobium, which is thought to be pathogenically linked to urothelial and squamous cell 
carcinoma of the bladder, making this cancer to have a greater concentration in areas with endemic 
infestation with this parasite (11-13). The underlying mechanism may lead to chronic irritation of 
the bladder epithelium, which may increase bladder cancer risk (5). 
Several studies showed that the use of drinking water containing chlorination by-products or 
contaminated by arsenic may increase the risk of bladder cancer (14, 15). An IARC Monographs 
Working Group reviewed in 2004 the relevant epidemiological studies and concluded that arsenic 
in drinking water is carcinogenic to humans (Group 1) and that there is sufficient evidence that it 
causes bladder cancer (5). 
It is believed that there is a slightly increased risk of bladder carcinomas development in patients 
who have undergone radiation therapy for prostate cancer (16).  
Most cases of urothelial carcinoma are seemingly present at patients over the age of 50 years, but 
they can also occur in younger adults and children (17, 18). 
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1.3.2.3. Clinical manifestations 
 
The urothelial carcinoma clinically is manifested by painless and intermittent haematuria, changes 
in the bladder’s habits or symptoms of irritations, etc. The type and severity of clinical signs and 
symptoms of infiltrating urothelial carcinoma depend on the extent and location of the tumour. 
Most patients with urothelial tumours present with at least microscopic haematuria. The most 
common presenting symptom of bladder cancer is painless gross haematuria which occurs in 85% 
of patients. Subsequent clotting and painful micturition may occur. In the case of large tumours, 
bladder capacity may be reduced resulting in frequency. Tumours located at the bladder neck or 
covering a large area of the bladder may lead to irritative symptoms, i.e. dysuria, urgency and 
frequency. Similar symptoms may be present in the case of extensive carcinoma in situ. Tumours 
infiltrating the ureteral orifice may lead to hydronephrosis, which is considered a poor prognostic 
sign. Rarely, patients with extensive disease present with a palpable pelvic mass or lower extremity 
oedema. In the case of advanced disease weight loss or abdominal or bone pain may be present due 
to metastases (19). 
 
 
1.3.2.4. Morphologic features  
 
The urothelium lines the inner surfaces of almost the entire urinary tract, including the renal pelvis, 
ureter, bladder and proximal urethra. Because it is the permeability barrier between urine and 
blood, the urothelium is constantly exposed to an assortment of potential carcinogens. It is of no 
great surprise then that urothelial carcinoma is one of the most common cancers worldwide (20). 
Urothelial tumours can arise anywhere in the bladder. In a series of 1,000 cases, the location was 
listed as follows: lateral walls, 37%; posterior wall 18%; trigone, 12%; ureteric orifices, 10%; dome 
8%; and anterior wall, 4%. Synchronous or metachronous multicentricity is common. Most clinical 
and molecular genetic evidence suggests that in the large majority of cases the tumours arise from 
a common clone and that therefore they are the consequence of intramucosal seeding of a single 
tumour rather than true multicentric neoplasms (19). 
The pattern of growth may be exophytic or endophytic, or a combination of both. When exophytic, 
the tumour may adopt a papillary or a villo-glandular configuration (with central fibrovascular 
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cores) or a solid (nodular) appearance (19). Carcinoma devoid of papillary structures is called 
carcinoma in situ (CIS) and is, by definition, high grade. Papillary tumours are also quite varied, 
including reactive proliferations and papilloma as well as the papillary urothelial proliferation of 
low malignant potential (PUNLMP) and low- and high- grade papillary carcinoma (21).  These 
carcinomas are graded as low and high grade depending upon the degree of nuclear anaplasia and 
some architectural abnormalities (5). 
Urothelial tumours may present as non-invasive or invasive patterns. Non-invasive tumours can be 
divided into two categories: flat or papillary. Stromal invasion by urothelial carcinoma proceeds in 
two stages: invasion of the lamina propria and invasion of the muscle layer (19). The most 
important element in the pathologic evaluation of urothelial cancer is the recognition of the 
presence and extent of invasion (5).  
Approximately 70% of bladder urothelial carcinomas are non-muscle invasive (Ta/T1), papillary 
tumours that are usually morphologically categorized as low-grade urothelial carcinoma. They 
have a good prognosis, which results in relatively long survival, but may be associated with 
recurrence and ‘progression’ to high-grade urothelial cell carcinoma (UCC) in approximately 10–
15% of cases. The remaining 30% are muscle-invasive (≥ T2) tumours, which are histologically 
categorized as high grade, are associated with worse overall survival than low-grade UCC and with 
a mortality rate of approximately 60% (22, 23).  
Detection of muscle invasion is of great consequence because of its influence on therapy and 
prognosis. This feature can be misinterpreted in case of inconsistent, but prominent fascicles of 
muscularis mucosae (particularly common in women) as belonging to the muscularis propria. 
Lymphovascular invasion may be present, but immunohistochemical studies for endothelial 
markers suggest that this feature can be closely simulated by retraction artefact. It is also important 
not to misinterpret the mature adipose tissue commonly present in the lamina propria or muscularis 
propria as perivesical soft tissue, in order to avoid a tumour adjacent to fat in a biopsy specimen 
being badly over-staged (19). 
Histologic variants. Urothelial carcinoma has a propensity for divergent differentiation with the 
most common being squamous followed by glandular. Virtually the whole spectrum of bladder 
cancer variants may be seen in variable proportions accompanying otherwise typical urothelial 
carcinoma. Histological variants may be as follows (5): 
1. Urothelial carcinoma with squamous differentiation 
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2. Urothelial carcinoma with glandular differentiation 
3. Nested variant 
4. Microcystic variant 
5. Micropapillary variant 
6. Lymphoepithelioma-like carcinoma 
7. Lymphoma-like and plasmacytoid variants 
8. Sarcomatoid variants 
9. Urothelial carcinoma with giant cells 
10. Urothelial carcinoma with trophoblastic differentiation 
11. Clear cell variant 
12. Lipid-cell variant 
13. Undifferentiated carcinoma.  
When small cell differentiation is present, even focally, it portends a poor prognosis and has 
different therapeutic ramifications, and hence should be diagnosed as small cell carcinoma (5) 
. 
 
1.3.2.5. Molecular genetic features 
 
Most epithelial tumours are thought to progress along a single pathway from benign to malignant 
by successive mutations in crucial genes that regulate growth, survival, apoptosis and cell-cell 
interactions. Urothelial carcinomas present as a heterogeneous group of diseases that consist of two 
main phenotypic variants with drastically different biological behaviours and prognoses. The low-
grade papillary variant (a classification that encompasses the terms urothelial papilloma, papillary 
urothelial neoplasm of low malignant potential, and non-invasive low-grade papillary urothelial 
carcinoma) accounts for about 80% of urothelial carcinomas and is often multifocal and recurrent, 
with limited potential to become muscle invasive (20). These tumours are thought to have 
originated from simple and nodular urothelial hyperplasia and, if treated early by surgical resection 
and intravesical (within the bladder) immunotherapy, the 5-year survival rate approaches 90%. The 
second main variant, which accounts for about 20% of urothelial carcinomas, presents as an 
invasive tumour and the patient usually has no previous history of low-grade non-invasive papillary 
tumours. These tumours seem to arise de novo or derive from flat, high-grade carcinoma in situ 
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(CIS) lesions. Despite radical cystectomy and debilitating systemic therapy, at least 50% of patients 
with invasive urothelial carcinomas die from metastases within 2 years of diagnosis. Treatment 
fails in 95% of patients with advanced disease, and the 5-year survival rate for metastatic bladder 
cancer is just 6% (20). 
 
 
1.3.2.6. Genetic and epigenetic alterations 
 
Numerous molecular factors are involved in determining UCC phenotype, genotype, biological 
behaviour, and clinical outcomes. Recent researches on urothelial carcinoma tumorigenesis have 
shown that urothelial carcinomas contain numerous genetic and epigenetic abnormalities, which 
could be categorized into four different levels: 1. Chromosomal level alterations that include 
numerical and/or structural anomalies of chromosomes, 2. Gene-level alterations that include 
genetic mutation, fragment deletions, amplification, or abnormal epigenetic changes, 3. Expression 
alterations and 4. Protein-level alterations that include up- or down-regulated protein expression, 
tumour-associated proteins, and fusion proteins (24). 
Numerical chromosomal alterations. Numerical chromosome aberrations represent changes of 
copy numbers of various genetic regions. The most frequent changes were observed on 
chromosomes 1, 8, 9, 10, 11, 13 and 14 (25). 
Structural chromosomal aberrations. Structural alterations involve gains, losses, translocations, 
or more complicated rearrangements of chromosomes, resulting in the alteration of DNA copy 
number at the chromosome level. Gains of material were detected on long arms of chromosomes 
1, 8 and 13 and losses of material on short arms of chromosomes 8 and 11 and on long arms of 
chromosomes 9, 10, 11 and 14. These alterations can be assessed by FISH, microsatellite analysis, 
SNP and CGH. Chromosome 9p21 deletion is frequently observed in the early stages of urothelial 
carcinogenesis (24, 25). Subsequent studies found both 9q and 9p losses in low-grade non-invasive 
papillary tumours and urothelial hyperplasia. Strikingly, even the normal-appearing urothelium 
that is adjacent to the tumour lesion harbours this chromosomal abnormality (26). These deleted 
regions harbour tumour-suppressor genes. For instance, the cyclin-dependent kinase inhibitor 2A 
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(CDKN2A) gene resides on 9p21 and encodes two alternatively spliced products, INK4A and 
ARF53, which induce cell-cycle arrest through the retinoblastoma protein (RB) and p53 signalling 
pathways, respectively (20). Other chromosomal anomalies such as a loss of 8p, which occurs in 
25–30% of urothelial carcinomas and is primarily associated with high-grade and late-stage 
tumours (27). 
DNA- sequence aberrations. DNA-sequence aberrations (mutations) are alterations in the DNA 
sequence of the genome that lead to various abnormalities such as the production of non-functional 
or truncated proteins, or destruction/generation of DNA methylation sites. Gene mutations 
frequently associated with TCC include loss of function mutations of TP53 and activation 
mutations of FGFR3, which characterize alternative genetic pathways in the pathogenesis of  
UCC (28). 
Major UCC-related molecular pathways. FGFR3 and TP53 mutations have been recognized as 
key genetic pathways in the carcinogenesis of transitional cell carcinoma. The first pathway is 
represented by FGFR3; activating mutations in the fibroblast growth factor receptor 3 (FGFR3) 
signalling pathway consequently activates the RAS-MAP kinase (RAS-MAPK) pathway and 
phospholipase Cγ (PLCγ), leading to uncontrolled cell proliferation (29). This appears to be the 
most frequently mutated oncogene in transitional cell carcinoma (60-80%). Its mutation is strongly 
associated with low tumour grade, early stage, and low recurrence rate, which confer a better 
overall prognosis. There are several other genes implicated in this pathway like Chromosome 9q 
deletion, HRAS, TSC1, PTCH, DBC1, PI3KCA etc. (19, 30).  
In contrast, the second pathway tumours, represented by TP53 mutations, are associated with 
higher tumour grade, more advanced stage, and more frequent tumour recurrences. Here also 
belongs the urothelial carcinoma in situ, which commonly shows mutations or deletions in the 
tumour suppressor genes TP53, RB and PTEN (24). The factors p53 (transcription factor) and RB 
(retinoblastoma) are the 2 key factors in the cell cycle regulation pathway, which is altered in 93% 
of bladder cancer cases (31). Factor p53, which is encoded by TP53, is the most famous and well-
studied tumour-suppressor and is inactivated by somatic mutations in approximately 50% of all 
human cancers (31, 32). TP53 mutations are highly frequent (>40%) in MIBCs, in contrast to the 
NMIBCs, of which only about 8% possess TP53 mutations (33). These molecular markers offer 
the potential to characterize individual urothelial neoplasms more completely than is possible by 
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histologic evaluation alone. Assessment of key genetic pathways and expression profiles could 
ultimately establish a set of molecular markers to predict the biological nature of tumours and to 
establish new standards for molecular tumour grading, classification, and prognostication (24). 
Epigenetic alterations. Unlike genetic mutations and copy number variation, epigenetic events 
regulate gene expression outcome without changing the underlying DNA sequence. Epigenetic 
regulation includes DNA methylation, histone modifications, microRNA regulation and 
nucleosome positioning, all of which are distorted in every form of human cancer (32). DNA 
methylation has been recognized to be important in developmental biology and cancer aetiology in 
general (34). DNA methylation of cytosine-guanine dinucleotide (CpG) islands involves the 
addition of a methyl moiety to the cytosine-5 position at a gene promoter region. This process alters 
gene function without changing the base sequence of DNA and has been recognized as a common 
alternative mechanism for gene inactivation, especially during the early stages of tumour 
development. There is growing evidence that methylation plays a pivotal role in the function of 
key gene promoters, blocking transcriptional activation (35). Cancer cells, including bladder 
cancer, show overexpression of DNMT1, DNMT3A, and 3B, which in turn results in DNA 
hypermethylation of promoter regions, and the possible subsequent silencing of tumour suppressor 
genes (36). Many tumour suppressor genes contain CpG islands and show evidence of methylation-
specific gene silencing associated with neoplasia. Hypermethylation of CpG islands is associated 
with transcriptional repression, whereas hypomethylation may lead to increased potential for gene 
activity or chromosomal instability (37). Mutations in the form of C→T transitions at methylated 
CpG sites are the hallmark of hydrolytic deamination of 5-methylcytosine and commonly produce 
mutations in tumour suppressor genes such as TP53 (38).  
In addition, a significant number of genetic mutations of epigenetic regulator genes occur in 
virtually every cancer type, thereby disturbing the epigenome patterns. These include somatic 
mutations of genes that encode for DNA methyltransferases, chromatin modifiers, and chromatin 
re-modelers. A substantial portion (76%) of all primary bladder tumours displays mutations in at 
least one chromatin regulatory gene (31). 
MicroRNAs (miRNAs) are short noncoding RNA molecules that modulate messenger RNA 
(mRNA) at the posttranscriptional level. They act as tumour suppressors or oncogenes and appear 
to be involved in cancer development and progression (24). The alterations of miRNA processing 
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genes/proteins and miRNA gene promoter hypermethylation are partly responsible for miRNA 
downregulation (39). Recent evidence suggests that alterations of miRNA expression contribute to 
urothelial carcinogenesis. 
 
 
1.3.2.7. Diagnosis 
 
In patients with signs suspicious for bladder cancer (e.g., haematuria), direct cystoscopic 
visualization of the bladder is the key diagnostic assessment followed by urine cytology and TUR 
(transurethral resection) with biopsy. The new technology including optical coherence tomography 
and confocal laser endomicroscopy may improve the sensitivity and specificity of identifying 
bladder tumours while also providing pathologic information (40). 
Histopathology remains the gold standard for bladder cancer diagnosis and it is the most important 
prognostic factor to predict clinical behaviour. Immunohistochemistry is very helpful in 
differentiating benign lesions from the malignant ones, as well as infiltrative focuses, using protein 
markers like P53, CK7/CK20, Ki67, CEA, TTF1, GATA3, MIB-1, etc. (19, 23). 
Urine cytology is a non-invasive method for detecting bladder cancer by identifying abnormal 
urothelial cells in the voided urine or bladder washes. Urine cytology has high specificity but 
relatively low sensitivity, particularly in well-differentiated low-grade bladder tumours. In order to 
improve the diagnostic sensitivity of urine cytology, the immunostaining of urothelial cells was 
developed to be applied to urine specimens.  
ImmunoCyt (DiagnoCure, Inc., Quebec, Canada) is a multiplex immune-cyto-fluorescence 
bladder cancer detection assay that combines fluorescently labelled monoclonal antibodies for 
M344, LDQ10, 19A211, and a glycosylated form of the carcinoembryonic antigen (CEA). A 
minimum evaluation of 500 epithelial cells is required, and the presence of one fluorescent cell is 
considered as positive. 
Fluorescent in situ hybridization is used to find molecular alterations in bladder cancer cells from 
the urine specimens. The UroVysion test (Abbott Molecular, Inc., Des Plaines, IL, USA) is a 4-
colour FISH assay designed to detect aneuploidy of chromosome 3, 7 and 17, as well as loss of the 
9p21 locus, using urine specimens from patients with haematuria. It consists of fluorescently 
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labelled DNA probes to the pericentromeric regions of chromosomes 3 (red), 7 (green), and 17 
(aqua) and to the 9p21 band (gold) location of the P16 tumour suppressor gene. The criteria for 
detecting bladder cancer by UroVysion are >4 urothelial cells with a gain of >2 chromosome 3, 7, 
or 17 or >12 cells with loss of the 9p21 locus. In addition, >10 urothelial cells showing a gain for 
a single chromosome 3, 7, or 17; or >10 cells with tetrasomy or near tetrasomy for chromosomes 
3, 7 and 17 are also considered abnormal (22). The advantage of uFISH test related to cytology is 
increased sensitivity for detection of all stages and grades tumours, especially in recurrent bladder 
cancer (41). 
These methods, except urine cytology, although having a high detection rate, are expensive, time-
consuming, invasive and uncomfortable (42). Patients with non-muscle invasive bladder cancer are 
regularly monitored for tumour recurrence and progression with cystoscopy and urine 
cytology. Therefore, there is a critical need for the identification of biomarkers to diagnose bladder 
cancer at an early stage, monitor recurrence, refine prognostic estimates, and predict response to 
treatment in patients with bladder cancer (42). 
 
 
1.3.2.8. TNM classification and staging 
 
The estimation of tumour stage is based on the TNM system which was created and is updated by 
the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer 
(UICC) WHO (5). 
T – Primary tumour 
TX: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Ta: Non-invasive papillary carcinoma 
Tis: Carcinoma in situ: "flat tumour" 
T1: Tumour invades subepithelial connective tissue 
T2: Tumour invades muscle 
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T2a: Tumour invades superficial muscle (inner half) 
T2b: Tumour invades deep muscle (outer half) 
T3: Tumour invades perivesical tissue: 
T3a: Microscopically 
T3b: Macroscopically (extravesical mass) 
T4: Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal 
wall 
T4a: Tumour invades prostate, uterus or vagina 
T4b: Tumour invades pelvic wall or abdominal wall 
 
N – Regional lymph nodes  
 
Nx: Regional lymph nodes cannot be assessed  
N0: No regional lymph node metastasis 
N1: Metastasis in a single lymph node 2 cm or less in greatest dimension  
N2: Metastasis in a single lymph node more than 2 cm but not more than 5 cm in greatest 
dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension  
N3: Metastasis in a lymph node more than 5 cm in greatest dimension 
 
M – Distant metastasis  
Mx: Distant metastasis cannot be assessed  
M0: No distant metastasis  
M1: Distant metastasis 
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1.4. Cancer, genomic instability and micronucleus formation  
 
Cancers are multifactorial diseases having a genetic basis, arising due to inherited mutations or de 
novo gained mutations in somatic tissues. Human cancers may be studied and examined at various 
levels of investigation. At the clinical level, cancers are usually recognized by clinical symptoms, 
such as abnormal tissue function and size, and can be visualized by conventional radioscopic 
methods. At the tissue level, after histological examination of sections from tumour biopsies, 
cancers are characterized by altered tissue morphology, structure and growth, metastasis, 
angiogenesis and lymph-angiogenesis. At the systemic level, changes in leukocyte levels may be 
monitored, and circulating factors may be associated with tumours. At the cellular level, for 
instance, cancer cells can be distinguished by abnormal centrosome numbers and conspicuous 
morphological changes (43). Furthermore, many common traits are found also at the protein level, 
especially in pathways that regulate replicative lifespan of cells. Remarkably, most cancer cells 
have either telomerase activity (90%), inactivated p53 and pRB pathways (50%), or abrogation of 
the INK4aARF locus (30%). Most importantly, the final diagnosis for cancer lies at the nuclear 
Stage Grouping  
Stage 0a         Ta                   N0             M0  
Stage 0is        Tis                  N0               M0  
Stage I            T1                  N0               M0  
Stage II           T2a, b            N0               M0  
Stage III          T3a, b            N0               M0  
                        T4a                N0               M0  
Stage IV          T4b                N0               M0                          
Any                 T                   N1, N2, N3   M0  
Any                 T                   Any N           M1 
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level. Cytogenetic analysis of cultured tumour cells reveals that most solid tumours have aneuploid 
karyotypes, i.e. aberrant nuclei with altered chromosome numbers and structure (43). 
It is commonly accepted that malignant transformation is a lengthy multi-step process and arises 
through an accumulation of mutations at various genetic loci. Most tumours arise through clonal 
selection and waves of expansion of a somatic cell that has acquired genetic alterations in essential 
genes either controlling cell death or cell proliferation (43). 
Several hundred genes, representing 1% of the human genome, have been implicated in 
tumorigenesis and progression, that means that tumour cells probably require only a small number 
of essential genes for cell proliferation (44). 
The integrity or completeness of genomic information is one of the fundamental prerequisites for 
life. To maintain this integrity, cells have many mechanisms, many of which have been the subject 
of recent studies. The relationship between genome stability and human health becomes more 
obvious in diseases typically characterized by progressive deterioration of specific tissues, 
susceptibility to cancer, chromosomal rearrangement, and hypersensitivity to genotoxic agents 
(45). In human tumour cells, some part of one, or more, of these mechanisms is disrupted, thus 
genomic integrity is easily broken down. This critically contributes to the malignant transformation 
of cells and cancer development (46). Furthermore, the stability of the genome in cancer cells 
becomes precarious and compromised because several cancer-predisposing mutations affect genes 
that are responsible for maintaining the integrity and number of chromosomes during cell division 
(43). 
Cancer cells typically harbour chromosomal alterations, such as aneuploidy or polyploidy and 
abnormal chromosome structures (47). A hallmark cause of these events is the chromosomal 
instability (CIN), which is observed in most solid tumour cells and is often associated with the 
missegregation of chromosomes that results from improper kinetochore-microtubule attachments 
and the consequent presence of lagging chromosomes during anaphase (48-50). One form of 
chromosome instability (CIN), the recurrent missegregation of whole chromosomes during cell 
division (W-CIN), leads to aneuploidy, a hallmark of most solid tumours. Tumour cells acquire 
W-CIN through three major mechanisms: mitotic checkpoint defects, centrosome 
overduplication or faulty sister chromatid cohesion. It promotes gains of extra copies of 
oncogenes or losses of tumour-suppressor genes, allowing the selection of karyotypes that thrive 
in certain environments. W-CIN leads to aneuploidy and the formation of micronuclei and 
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binucleate cells (51). The genomic instability due to changes in chromosomal structure named as 
structural CIN (S-CIN), in form of translocations, deletions, inversions and chromosomal 
fragmentation, as a result of poor repair of damaged DNA (52). Genetic instability is a transient or 
a persistent state that causes a series of mutational events leading to gross genetic alterations. It is 
now clear that most cancers have altered genomes. Genetic instability has been found in many 
types of cancer (43). 
Cells continuously encounter DNA damage either through endogenous sources (including radical 
species as by-products of cellular metabolism) or through exogenous sources (such as ultraviolet 
rays in sunlight). In order to maintain genetic stability while being under constant assault, 
evolutionary conserved pathways exist that can detect and repair DNA damage which are 
collectively termed the DNA damage response (DDR)(53). A specifically toxic type of DNA 
damage are double strand breaks, which can be repaired using two mutually exclusive types of 
DNA repair; non-homologous end-joining (NHEJ) which ligates two ends of the broken template 
and it is inherently prone to generating mutations, or homologous recombination (HR) which 
usually uses the DNA of the sister chromatid as a template to repair the damaged DNA, and is not 
prone of generating mutations (52). Even though cells are equipped with several repair systems 
and cell cycle checkpoints that prevent cells with damaged DNA from undergoing mitosis, cells 
can end up in mitosis through several paths in the presence of DNA breaks, including checkpoint 
failure and mitotic processing of replication aberrancies (52). Various errors in DNA replication, 
DNA repair and chromosome segregation during mitosis and cell cycle checkpoint defects can lead 
to the physical isolation of chromosomes or fragments of chromosomes - which could induce the 
formation of micronuclei (MNi) (54), to defective separation of sister chromatids - which could 
result with nucleoplasmic bridges (NPBs) formation, and  DNA amplification - which elimination 
could result in nuclear buds (NBUDs) formation (55). Chromosome breakage, loss and 
rearrangement are important initiating events in cancer; however, they also play an important role 
during the evolution of cancer when a genome instability phenotype is established (56).  The use 
of biomarkers of chromosomal damage due to genetic instability in order to predict the risk of 
cancer as well as to identify high-risk individuals is both valuable and imperative (57). In the last 
decades, they are extensively used for early detection of biological effects of DNA-damaging 
agents and genome instability (58-60). 
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1.4.1. Mechanisms of micronuclei, nucleoplasmic bridges and nuclear buds formation 
 
1.4.1.1. Micronucleus formation 
 
Micronuclei are defined as small chromatinic bodies that appear in the cell cytoplasm, lagging 
behind the cell division (61). MN, also known as Howell–Jolly bodies, were originally identiﬁed 
and described in erythrocytes by the haematologists William Howell and Justin Jolly and they were 
later found to be associated with deﬁciencies in vitamins such as folate and vitamin B12 (62). 
 
 
Figure 1. (A) Schematic diagram showing the origin of MN from either a lagging chromosome 
fragment or a whole chromosome. (B) A photomicrograph of a mitogen-stimulated, cytokinesis-
blocked lymphocyte containing one MN. Adopted from Bonassi S et al (63). 
 
It is now well-established that MN mainly originates from acentric chromosome fragments, 
acentric chromatid fragments or whole chromosomes that fail to be included in the daughter nuclei 
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at the completion of telophase during mitosis because they did not attach properly with the spindle 
during the segregation process in anaphase. These displaced chromosomes or chromosome 
fragments are eventually enclosed by a nuclear membrane and, except for their smaller size, are 
morphologically similar to nuclei after conventional nuclear staining (55). 
As MNi derive from chromosomal fragments and whole chromosomes lagging behind in anaphase, 
the MN assay can be used to show both clastogenic and aneugenic effects. The distinction between 
these phenomena is important since the exposure studied often induces only one type of MN.  MN 
harbouring chromosomes can be distinguished from those harbouring acentric fragments by the 
presence of a centromere. The proportion of centromere-positive MN in human lymphocytes 
increases with age, which primarily reflects an age-dependent micronucleation of the X and Y 
chromosomes. The X chromosome especially tends to lag behind in female lymphocyte anaphase, 
being micronucleated (MNed) more efficiently than autosomes. Sex chromosomes contribute the 
majority of chromosome loss events with increasing age, and the X chromosome can account for 
up to 72% of the observed MN in female (64).  The possible mechanism includes hypomethylation 
of cytosine in centromeric and pericentromeric repeat sequences such as classical satellite repeats 
at pericentromeric regions and higher-order repeats of satellite DNA in centromeric DNA (65). 
There is some evidence for an enhanced prevalence of fragments from chromosome 9 in 
spontaneous human lymphocyte MN and from chromosomes 1, 9 or 16 in MN induced in vitro by 
some clastogens; the breakage appears to occur in the heterochromatic block of these 
chromosomes. Understanding the mechanistic origin and contents of MN is essential for the proper 
use of this cytogenetic end-point in biomarker studies, genotoxicity testing and risk assessment 
(64).  
As research on the MN advances, extremely varied origins of MN and MN-like structures are 
emerging. It is thought that MN are not only caused by chromosome segregation failure in mitosis 
itself, but also can result from a wide variety of stresses occurring during any of the previous stages 
of the cell cycle. The underlying pathways that drive MN are complex and heterogeneous. Based 
on the time when the first hit of micronucleation occurs, the origins of MN can be divided into four 
groups: mitotic, pre-mitotic, post-mitotic and interphase origins (Figure 2) (54). 
Mitotic origin of MN. Mitosis is a key process related to micronucleus formation. Supported by 
direct live-cell imaging of young, middle-aged and old-aged primary human dermal fibroblasts, a 
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recent study finds that MN increases with ageing due to general dysfunction of the mitotic 
machinery (66). Accurate chromosome segregation during cell division ensures that each daughter 
cell inherits a complete and identical copy of the genome. Chromosome segregation is driven by 
the centromeres and mitotic spindle, a self-organizing micro machine composed of microtubules 
and associated proteins. Kinetochore, the protein complex assembled at each centromere on each 
chromosome, serves as the attachment site for spindle microtubules. Faithful chromosome 
segregation is ensured by the bi-oriented (amphitelic) kinetochore–microtubule (k–MT) 
attachments  (67). Since microtubules capture kinetochores randomly, erroneous k–MT 
attachments can form. These include monotelic attachments (only one kinetochore in the pair binds 
to microtubules) and syntelic attachment (both kinetochores are attached to microtubules 
emanating from the same centrosome). In normal cases, the incorrectly attached kinetochores 
generate the “waiting signal” for the spindle assembly checkpoint (SAC), which delays the 
activation of the anaphase promoting complex/cyclosome (APC/C). APC/C is a ubiquitin-protein 
ligase that promotes the proteasomal destruction of securin, an inhibitor of separase, and the cyclin 
B (68). When the SAC deficiency exists, cells with monotelically attached or unattached 
chromosomes are formed, and they may progress to anaphase (69)  and the laggards are prone to 
be subsequently incorporated into MN (48). Thus, SAC is the major cellular regulatory system 
acting during mitosis to prevent MN formation, so SAC dysfunction: insufficiency and 
overexpression of SAC proteins, are linked to micronucleation (54). 
Pre-mitotic MN. Besides the dysfunction of the mitotic apparatus, chromosome breakage is also 
a factor leading to the formation of MN. Acentric chromosome fragments are formed pre-
mitotically, as a result of unrepaired DNA double-strand breaks (DSBs) caused by pre-mitotic 
DNA replication stress or as a result of mis-repair of DNA breaks (70), (71). Acentric chromosome 
fragments are particularly prone to micronucleation because they are incapable of forming normal 
attachments with the mitotic spindle (72). During metaphase, acentrics localize to the outer edge 
of the metaphase plate, separated from the main mass of chromosomes. On entry into anaphase, 
they remain in this position while the main mass of sister chromosomes separates. During the late 
anaphase, some of the acentrics segregate to correct poles (73). The fragments that fail to segregate 
are generally encapsulated by the reformed nucleoplasmic envelope to generate MN (74). 
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Double minutes (DMs) are acentric fragments of extrachromosomal circular DNA (eccDNA) 
mainly found in human tumours. They are composed of acentric, atelomeric, and autonomously 
replicating chromatin consisting of a few mega-base pairs in size (75). DMs are formed from 
amplified DNA and, when occurring in cancers, they usually contain oncogenes or resistance genes 
that contribute to the over-proliferation potential of cancer cells. The mechanism of DMs formation 
is initiated by dicentric chromosomes due to the misrepair of DNA breaks by non-homologous end 
joining (NHEJ) (76). At anaphase, the dicentric chromosome is pulled to opposite poles of the cell. 
The break of dicentric chromosomes leads to breakage-fusion-bridge (BFB) cycles and DNA 
amplification, which is a key driver to chromosomal instability. Subsequently, the amplified DNA 
is eliminated as a mini-circle by a recombinational mechanism (55, 77). In addition, recombination 
of telomeres with interstitial telomere-related sequences results in a terminally deleted 
chromosome with a shortened telomere, as well as some DM containing telomeric DNA (78). DMs 
may stick to normal chromosomes at the time of mitosis, allowing them to be transmitted to 
daughter cells in a stable manner (79). However, some cells contain aggregates of DMs that are 
left behind from chromosomes at anaphase, which leads to their micronucleation at telophase when 
the reconstruction of nuclear membrane proceeds. DM-type MN formed in this way are normally 
lamin B positive (80). Overall, the physical separation of laggard chromosomes or chromatin 
fragments from the remaining faithfully segregating ones during anaphase can lead to their 
exclusion from the primary nucleus and micronucleation in the subsequent G1phase of the cell 
cycle because of nuclear envelope reassembly happens before the laggards join the mass of 
segregating chromatids. Laggards are a leading cause of MN, as it accounts for 63.9% of 
spontaneously generated MN in HeLa cells (81). 
Post-mitotic origins of MN. In mammalian cells, NHEJ is a predominant pathway of DSBs repair 
by searching for neighbouring DNA molecules to re-join the broken end. If this process occurs in 
G2 and each of the sister chromatid presents a DSB as well, then the two sister chromatids will 
likely be fused to create a circular or dicentric chromosome. Such fused chromosome is unable to 
separate in anaphase, and will, therefore, form a chromatin bridge (CB) spanning the spindle 
midzone (54). In addition to DSBs, CB can be caused by telomere fusion (82), replication stress 
(83) or persistent chromatid cohesion (84). CBs are highly elastic and rarely break during anaphase 
(82, 85), ruling out stretching by the elongated mitotic spindle as the cause of breakage. After 
anaphase, CBs can be severed in various ways. In human colorectal COLO320DM tumour cells, 
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breakage of the CBs occurs prior to nuclear membrane reformation and the completion of 
cytokinesis, indicating that mechanical tension rather than cytokinesis is primarily responsible for 
severing CBs (75). Some of them can persist beyond the completion of mitosis, which may be 
resolved by the cytoplasmic 3′nuclease TREX1 at 3–20h after anaphase, before the primary nucleus 
(PN) enter S phase (82). Often the resolution of CBs gives rise to MN in one or both daughter cells 
at the end of mitosis (83, 86, 87), because intrinsic structural features, make some regions of CBs 
more easily to stretch and broke (75). It has been estimated that 9.25% of the spontaneously arising 
MN in HeLa cells can be attributed to CBs breakage (81). MN generated from CB breakage are 
negative for Lamin B2 (88). Whether the bridged chromosome ends up in the PN or in an MN 
seems to depend on the extent of the length differential between the two k-fibers bound to the 
bridged kinetochores (85). It should be mentioned that MN arising from the breakage of telomere 
fusion-induced CBs is extremely low (82). However, this does not mean telomere fusion is not 
linked to micronucleation. Alternatively, dicentric chromosomes induced from telomere fusion 
give risk to MN because they have a high tendency to be lagging during anaphase. This finding 
suggests that pulling a dicentric chromosome toward opposite poles can generate the necessary 
force for detaching this chromosome from the microtubules of one or both spindle poles (87).  
Observations done in HeLa cells have prescribed an unusual way for MN generation: cell fusion 
after multipolar mitosis and incomplete cytokinesis (81). The presence of extra centrosomes leads 
to the formation of a multipolar mitotic spindle, which if fails to cluster their centrosomes prior to 
anaphase, results in the segregation of chromosomes into more than two daughter cells. Because 
of the different levels of chromosomal capture and alignment on each pole, multipolar mitosis 
causes the near-to-stochastic distribution of chromosomes. In extreme cases, one pole might 
receive only a small amount of chromosomes that resembled the lagging chromosome mass (46). 
Thus, depending on the nuclei size of the two fused daughter cells, either a binucleated or an MNed 
cell will arise at the end of cytokinesis. MN formed in this manner may contain more than one 
chromosome, and are found to be much larger than those formed by other mechanisms (81). 
Interphase origins of the MN. Nuclear morphology is an important factor in the proper 
organization and maintenance of gene expression. Most healthy cells have round or ellipsoid 
nuclei. Some healthy cell types and some cancer cells exhibit nuclear material protrusion, forming 
nuclear buds or blebs, which are thought to be sources of MN formed during interphase. The 
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interphase origin of DM-type MN has been assumed based on the study of the correlation between 
the frequencies of nuclear buds and MN in fixed interphase cells (89). According to this model, 
DM are frequently localized at the periphery of the nucleus and can be extruded through nuclear 
budding and detachment of chromatin from the PN into the cytoplasm (79). About 2–3% of the 
cells with reduced levels of Lamin B1 showed prominent nuclear blebs, which eventually become 
nuclear buds and totally separate from the PN and form MN (90). This is a key step in interphase 
MN generation (91). Lamin B1 depletion is also known to increase to the frequency of lagging 
chromosomes, suggesting that MN in Lamin B1 depleted cells also have a mitotic origin (92).  
Utani et al. revealed that membrane blebbing occurred simultaneously with the extrusion of nuclear 
content (93). Activation of cytoplasmic membrane blebbing induces nuclear budding, suggesting 
that blebbing may play a key role in nuclear budding through cytoplasmic membrane dynamics 
(93).  
Nucleoli are recently found to be a new region for MN biogenesis. Nucleoli form at the end of 
mitosis around the randomly repeated clusters of ribosomal DNA genes and result in a subnuclear 
compartment that locally concentrates the transcription and processing machinery that are 
responsible for generating ribosome subunits (94). 
Overall, interphase-originated MN is rarely observed and restricted to specific conditions and 
species. Little is known about their frequency in somatic and cancer cells, as well as for the genetic 
material inside them (54).  
 
24 
 
 
Figure 2. Different routes leading to MN formation. The underlying pathways that drive MN are 
complex and heterogeneous. Typically, the pathways underlying MN formation can be divided into 
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four groups: mitotic (A–E), pre-mitotic (F and G), post-mitotic (H–J) and interphase (K–O) origins 
(See further description in text). Abbreviations: SAC, spindle assembly checkpoint; DM. Double 
minutes; CB, chromatin bridge; NE, nuclear envelope; NoA, nucleolar aggresomes. Adopted from 
Guo X et al (54). 
 
 
1.4.1.2. The origin of nucleoplasmic bridges 
 
NPB originate during anaphase when the centromeres of dicentric chromosomes are pulled to 
opposite poles of the cell during mitosis. In the absence of breakage of the anaphase bridge, the 
nuclear membrane eventually surrounds the daughter nuclei and the anaphase bridge, and in this 
manner, an NPB is formed (Figure 3). NPB are usually broken during cytokinesis but they can be 
accumulated in cytokinesis-blocked cells using the cytokinesis inhibitor cytochalasin-B. Dicentric 
chromosomes originate either from misrepair of chromosome breaks or telomere to telomere end 
fusions (71, 55)  
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Figure 3. Pancentromeric and telomeric probes can be used to distinguish (I) between MNi 
originating from whole chromosome loss (a) and MNi originating from acentric chromosome 
fragments (b) and (II) NPBs from dicentric chromosomes resulting from misrepair of DNA strand 
breaks (b) and dicentric chromosomes caused by telomere end fusions (c). The yellow dots 
represent probes that hybridize to the centromeric region of chromosomes. The light blue dots 
represent probes that hybridize with the telomeric sequences in chromosomes. Adopted from 
Fenech M et al (95). 
 
Telomeres are DNA–protein complexes that contain short repeat sequences added on to the ends 
of chromosomes by the enzyme telomerase. Telomeres serve multiple functions, including 
protecting the ends of chromosomes and preventing chromosome fusion. Loss of telomere function 
leading to chromosome fusion can occur through a variety of mechanisms, involving either 
endogenous events or exogenous DNA damage. Chromosome fusion can result from the loss of 
capping function when telomeric repeat sequences are still present, or through the loss of sufficient 
telomeric repeat sequences to maintain a functional telomere (96). The latter are caused by 
inappropriate assembly of the telosome protein structure that encapsulates and protects the telomere 
either because of excessive telomere shortening or deletion and/or base damage in the telomere 
sequence (87, 96).  
Failure to cap the 3’ single-stranded G-rich overhang at the end of the telomere may result in the 
chromosome ends being perceived as broken DNA molecules in which case they may be repaired 
by the DNA end-joining mechanism and cause telomere end fusions (97, 98); the latter may also 
be increased due to defects in recombinational repair proteins (98). These mechanisms of 
nucleoplasmic bridge formation can be distinguished using telomere probes, in cytokinesis-blocked 
binucleated cells. NPB originating from telomere end fusions are expected to be telomere positive 
if they retain telomere sequences and/or if the fusions are caused by telomere dysfunction due to 
loss of telomere-binding proteins without telomere attrition; however, if the fusion was caused due 
to complete erosion of telomere sequence, the NPB originating from such a mechanism can only 
be recognized with a speciﬁc probe that hybridizes in the subtelomeric region adjacent to the 
telomeric repetitive sequence track (95, 98, 99). In contrast, an NPB caused by misrepair of DNA 
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breaks has a low probability of occurring within the telomeric sequences and is therefore likely to 
be telomere negative (71, 95). Furthermore, NPB arising from misrepair of DNA breaks are also 
likely to be associated with a MN originating from the acentric fragment generated during misrepair 
(71, 100). However, a MN originating from an acentric fragment may not necessarily accompany 
a telomere end fusion event because the latter can occur in the absence of DNA strand breakage 
and misrepair (54). 
 
 
1.4.1.3. The origin of nuclear buds 
 
Nuclear buds, micronucleus-like bodies attached to the nucleus by a thin nucleoplasmic connection, 
have been proposed to be generated similarly to micronuclei during nuclear division or in S-phase 
as a stage in the extrusion of extra DNA (amplified DNA), possibly giving rise to micronuclei 
(101). Shimizu et al. (102) used in vitro experiments with mammalian cells to show that amplified 
DNA is selectively localized to specific sites at the periphery of the nucleus and is eliminated via 
nuclear budding during S phase of the cell cycle. The NBUD are characterized by having the same 
morphology as an MN with the exception that they are connected to the nucleus by a narrow or 
wide stalk of nucleoplasmic material depending on the stage of the budding process. It is also 
reported that MN may also be formed by a budding process following exposure to γ-irradiation 
(103). NBUD have also been shown to be formed when an NPB between two nuclei breaks and 
the remnants shrink back towards the nuclei (46). 
Using centromere and telomere probes, Lindbergh et al. (101) investigated the mechanisms of MN 
and nuclear bud formation in folic acid-deﬁcient cells. Their results suggest that NBUD and MN 
have a partly different mechanistic origin. Interstitial DNA without centromere or telomere labels 
was clearly more prevalent in NBUD (43%) than in MN (13%). Telomeric DNA only or both 
centromeric and telomeric DNA was more frequent in MN (62 and 22%, respectively) than in 
NBUD (44 and 10%, respectively). Folate deprivation increased the frequency of NBUD and MN 
harbouring telomeric DNA, NBUD harbouring interstitial DNA and also NBUD and MN with both 
centromeric and telomeric DNA. According to this model, MN in binucleate lymphocytes 
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primarily derive from lagging chromosomes and terminal acentric fragments during mitosis; 
however, most NBUD originate from interstitial or terminal acentric fragments. Such NBUD may 
possibly represent nuclear membrane entrapment of DNA that has been left in the cytoplasm after 
nuclear division or from excess DNA that is being extruded from the nucleus (101). 
 
 
1.4.2. Micronuclei fate profiles 
 
Persistence. The most general outcome of MN is persistence, where micronucleated (MNed) 
chromatins/chromosomes keep their MN state during one or more following cell cycles. After the 
complete division of MNed cancer cells, most of the MN (62%) can persist into the second 
generation cells (104). Most strikingly, MNed cells showed a very consistent outcome over 
subsequent divisions; ∼70% of the divisions led to the maintenance of MN at the end of the first 
division and in the remaining ∼30%, micronuclei were reincorporated; ∼75% of the daughter 
MNed cells maintain their MN after the second division, remaining ∼25% of them reincorporated 
the micronucleus  (105). 
The high tendency for MN to persistence suggests it is a regulated process, rather than a result of 
the stochastic distribution. Yet, the underlying molecular mechanism remains elusive. One 
explanation is the centromere of MN-enclosed chromosomes become damaged and lack proper 
kinetochores and are therefore unable to be aligned at the metaphase plate prior to anaphase onset 
[74]. Upon their formation, micronuclei already display decreased levels of important kinetochore 
assembly factors. Importantly, these defects favour the exclusion of the micronucleus over the 
reintegration into the primary nucleus over several divisions (105). 
The lack of proper DNA replication could also explain the high frequency of MN persistence. 
Whether the persisted MN undergo DNA replication is controversial. It has been revealed that 
DNA synthesis takes place in a portion of MN that contain nuclear Lamin B1in the S phase before 
the next mitosis, whereas MN lacking Lamin B1 are never replicated (106), meaning that for DNA 
replication, the maintenance of Laminin B1 levels is required. DNA replication in MN is 
asynchronous with PN, with replication in MN persisting in otherwise G2 cells, due to improper 
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nuclear pore complexes (NPCs) assembly that prevents proper loading of replication proteins 
(104). In contrast, some MN may contain as many as ten copies of centromeric signals for X 
chromosome (107), indicating MN can be retained and replicated in the cytoplasm for more than 
one cell cycle. This was considered a speculative possibility, while there is evidence that multiple 
centromeric signals might simply be the consequence of centromere repeats expansion or 
neocentromere formation (108). Unreplicated chromatids can only form monopolar attachments 
that fail to align properly during cell division. There seems to be a slight bias for replication-
deficient MN to be maintained as MN (105). It can be hypothesized that MN that suffer more from 
replication defects most likely also suffer more from other defects that could interfere with 
chromosome segregation (54). 
Reincorporation. The mitosis of some MNed cells leads to the production of two apparently 
normal daughter cells, indicating that MN can be reincorporated into PN during the next mitosis 
(48, 104). The reincorporation frequency during the next mitosis is estimated to be 0–38%, 
depending on the cell type and the mode of MN induction (105, 104). Two different scenarios of 
reincorporation have been observed in human cells, depending on the centromere function inside 
MN: (1) Chromosomes in MN with an intact centromere are able to assemble kinetochore, 
congregate onto metaphase plate, separate and segregate into one daughter nuclei randomly (48). 
In some cases, chromosomes in an MN that has been replicated can separate equally during mitosis 
and rejoin in the PN of a daughter cell after division (109). (2) MN that do not condense nor 
associate with the other chromosomes during the next mitosis but can be enclosed into the daughter 
nucleus as nuclear envelope (NE) reassembly at the end of mitosis due to their close distance (104) 
being located in the periphery of daughter nuclei (105). Interestingly, the defects observed in 
micronuclei are likely overcomed once micronuclei are reincorporated into the primary nuclei, as 
they further propagate normally. Using long-term live cell imaging, a study shows that cells with 
the reincorporated MN do not exhibit new MN formation in the subsequent division, suggesting 
that kinetochore impairments in MN are likely overcomed when they are reincorporated into the 
nucleoplasm of PN (105). 
Disruption. The NE is a physical membrane barrier that separates the nucleus from the cytoplasm. 
It fulfils at least two essential functions in eukaryotic cells: first it regulates the movement of 
molecules between the nucleus and the cytoplasm by active, signal-dependent transport via 
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aqueous channels that are formed by the NPCs, and second it creates a permeability barrier that 
prevents the passive diffusion of molecules larger than ~40 kDa across the NE. An intact nuclear 
permeability barrier is generally considered to be a prerequisite for nuclear transport and to be 
critical for proper cell compartmentalization (110). MN is thought to have the same structure of 
their nuclear envelope as PN. Early observations using electron microscopy revealed that some 
MN display an incomplete NE, with gaps in the double membrane and areas without lamina or 
condensed chromatin (111). This finding challenged the traditional view that MN are structurally 
similar to PN. Recent evidence has shown that over 60% of MN in cancer cells undergo an 
irreversible loss of compartmentalization due to NE collapse. MN disruption occurs throughout 
interphase and independently of MN origin (whole-chromosome origin and chromatin fragment 
origin) (112).  
The molecular mechanisms implicated in NE fragility of MN are only partially discovered. It has 
shown that disrupted MN are frequently smaller and more condensed than intact MN. Defective 
NPC reassembly and disorganization/lack of Laminin B1, are shown to be indicators of the 
disrupted nuclear envelope in MN (112). 
NE is a determinant factor that influences the functional integrity of MN, such as repair of the DNA 
lesions (113). Compared with intact MN, DNA transcription and replication are completely 
abolished in disrupted MN, and repair of existing and new DNA damage is also significantly 
compromised (112). The dysfunction of MN may be primarily due to the loss of Lamin B1 and 
NPC integrity. Therefore, NE collapse in MN may partially explain why MN have reduced 
functions compared to PN in the same cell. 
Another factor that is thought to promote NE rupture is high nuclear curvature (114). Since the 
nuclear curvature of NE in MN is more extreme than that of PN, it can be a root cause of the high 
NE fragility of MN.  It has been found that mitochondria mislocalize into the PN following NE 
rupture (110). It will be interesting to determine whether mitochondria are also present in disrupted 
MN. If dysfunctional mitochondria are present also in disrupted MN, it probably could further 
contribute to DNA damage by producing excessive reactive oxygen species, and it is speculated 
that this process could contribute to the shattering of MNed chromosomes after MN disruption 
(115). However, a recent study has shown that the chromatin from disrupted MN can persist into 
the next cell cycle and participate in a phenomenon called chromothripsis, which is defined by 
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small-scale DNA copy number changes and extensive intrachromosomal rearrangements that are 
restricted to a single chromosome or chromosome arm (116). 
Degradation. MN can be subject of autophagic degradation. Autophagy is a cellular catabolic 
process by which cytoplasmic waste is engulfed in a double-membrane vesicle and delivered to the 
lysosomes for breakdown and eventual recycling. Although some studies demonstrate that MN do 
not colocalize with lysosome markers (104), cells with an increase in MN manifest an increase in 
autophagic marker LC3 and the inclusion of MN inside autophagosomes, demonstrating MN can 
be subjected to autophagic degradation (117, 118). The DNA in MN is found to be transported to 
lysosome by autophagosomes and be degraded thereby ubiquitously expressed lysosomal DNA 
endonucleases, including DNase2 (119, 120). Inhibition of autophagy or these DNases is found to 
associate with a significant increase of MN frequency (120, 121).  
It is surprising that the proportion of MN undergoing autophagic processing is small (∼2-5%) and 
autophagic MN are observed alongside clearly non-autophagic MN in the same cell (117). One of 
the reasons that may explain why MN are only rarely sequestered in autophagosomes is their size. 
However, the finding that MN-like structures sized up to10μm are subjected to autophagy (122) 
may preclude this possibility. Although the mechanisms underlying these phenomena require 
further discussion, a promising model linking MN autophagy to the failure of DNA repair in MN 
has been proposed (123). 
Some studies have suggested that DNA in MN may also be degraded by apoptosis. Although there 
is no evidence of a premature or localized activation of the apoptosis pathway, it’s interesting to 
see whether MN apoptosis represents the very early step of the apoptosis of whole MNed cell. It 
should be emphasized that apoptotic-like MN degradation is only observed in fixed cells but never 
observed in live-cell experiments (104, 112). 
Extrusion. MN extrusion was first observed during the in vivo maturation of erythrocytes, and 
MN harbouring whole chromosomes are preferentially extruded (124, 125). In cancer cells, the 
extrusion of MN mediates the selective elimination of DM, and the extracellular MN have 
decondensed chromatin and intact lamin protein, and their DNA did not suffer any extensive 
degradation (102). In most cases, the extruded MN are surrounded by the cytoplasmic membranes, 
forming a cell-like structure (minicell). Whether MN extrusion exactly occurs remains 
controversial since it’s never observed in live imaging studies (104). 
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1.5. Micronucleus assay and micronucleus index 
 
The micronucleus was recognized at the end of the 19th century when Howell and Jolly found 
small inclusions in the blood taken from cats and rats. The small inclusions, called Howell-Jolly 
body, are also observed in the erythrocytes of peripheral blood from severe anaemia patients. These 
are the first description of the micronucleus itself (126). In 1959, Evans et al. did the first report 
attempting to evaluate chromosomal aberration by the frequency of cells harbouring micronucleus 
(127). In 1970, Boller and Schmid (128) developed a test method to evaluate the frequency of 
MNed erythrocytes among normal erythrocytes, which lack their own nuclei during 
haematopoiesis, using bone marrow and peripheral blood cells of Chinese Hamster treated with a 
strong alkylating agent, trenimon. In the paper, they named this method "Mikrokern-Test". They 
built the basics of nowadays “micronucleus test” (126), which was adopted to be performed in the 
different type of cells, in dozens of scientific investigations. In 1976, Countryman and Heddle (129) 
reported a method using human cultured lymphocytes. Modifications have been introduced by 
Fenech and Moley (130) using cytochalasin B. Later called as „cytokinesis-block micronucleus 
assay “(CBMN), this method was widely used for human biomonitoring of DNA damage. 
The CBMN assay has evolved into a comprehensive “cytokinesis-block micronucleus cytome 
assay” that is used to measure not only chromosome breakage as a consequence of mutagen 
exposure but also chromosome loss, non-disjunction, DNA misrepair, necrosis, apoptosis and 
cytostasis in PBL (131). 
The MN assay in PBL is a well-established method, that measures the frequency of MNi, usually 
reported as the number of cells containing MNi per total cells counted. The DNA damage events 
in PBL are specifically scored in once-divided binucleated (BN) cells that have completed the 
nuclear division but have been blocked at the binucleated stage prior to cytokinesis. The events 
scored include the following: (a) micronuclei, a biomarker of chromosome breakage and/or whole 
chromosome loss; (b) nucleoplasmic bridges, a biomarker of DNA misrepair and/or telomere end-
fusions, and (c) nuclear buds, a biomarker of elimination of amplified DNA and/or DNA repair 
complexes (132).  
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Figure 4. The various possible fates of cultured cytokinesis-blocked cells following exposure to 
cytotoxic/genotoxic agents. Using these biomarkers within the CBMN assay, it is possible to 
measure the frequency of chromosome breakage (MN), chromosome loss (MN), chromosome 
rearrangement, for example, dicentric chromosomes (NPB), gene amplification (NBUDs), necrosis 
and apoptosis. In addition, cytostatic effects are readily estimated from the ratio of mono-, bi- and 
multinucleated cells. Adopted from Fenech M et al (95). 
 
This assay was first used in exfoliated cells in 1984 by Stich et al. (133), and continue being one 
of the most preferred micronucleus tests due to easier accessibility and non-invasiveness. More 
than 90% of cancers arise in epithelial tissues (134). Exfoliated epithelial cells have traditionally 
been used for cancer screening by cytopathologists, and these cells can also be used for 
biomonitoring of the genotoxic effects in humans (135). The epithelial cells are in immediate 
contact with inhaled and ingested genotoxic agents, and bladder cells are also in contact with 
metabolites of the chemicals (134), thus, the chromosomal damage caused by carcinogens to 
dividing basal cells of the epithelium results in the production of micronuclei in the daughter cells, 
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which migrate up through the epithelium and are exfoliated. Exfoliated cells can be readily 
obtained from several tissues, including the oral buccal mucosa (scrapings of oral cells), bronchi 
(sputum), urinary bladder and ureter (centrifugation of urine), cervix (smears) and oesophagus 
(imprints from biopsies) (133). 
The MN index appears to increase in carcinogen-exposed tissues long before any clinical 
symptoms are evident (136). 
Measurement of micronucleus (MN) index in peripheral blood lymphocytes (PBL) is extensively 
used in molecular epidemiology and cytogenetics to evaluate the presence and the extent of 
chromosomal damage in human populations exposed to genotoxic agents or bearing a susceptible 
genetic profile (63). In the last years, the CBMN assay has become a thoroughly validated and 
standardized technique to evaluate in vivo radiation exposure of occupational, medical and 
accidentally exposed individuals. There is a number of studies (137, 138) that used this assay as a 
biological dosimeter for detecting DNA anomalies in cancer patients treated with different doses 
of radiation. They revealed that after the completion of radiotherapy, the persistence of elevated 
MN yield in PBLs was a reflection of the surviving population of radiation-induced genetically 
aberrant cells (137). There are studies indicating the effect of chemotherapeutics in MN formation 
due to DNA damage. The anticancer mechanism of antineoplastic drugs is the generation of 
reactive oxygen species (ROS) which are responsible for various side effects in patients undergoing 
chemotherapy and the healthcare personnel occupationally exposed to them (139-141).  
Some meta-analyses and nested studies, show that chronic ingestion of arsenic in drinking water 
(142, 143), lifestyle habits (tobacco smoking and alcohol consumption, micronutrient deficiencies) 
(77, 144-148), occupational exposure to formaldehyde, polycyclic aromatic hydrocarbons, 
petroleum, pesticides, organic solvents, etc. (61, 149-154) are linked to the enhanced incidence of 
micronuclei in all three types of cells, slightly higher level of micronuclei being observed in 
lymphocytes compared with oral mucosa and urothelial cells. 
It was found that a deficiency of any of the micronutrients: folic acid, Vitamin B12, Vitamin B6, 
niacin, Vitamin C, Vitamin E, iron, or zinc, mimics radiation in damaging DNA by causing single- 
and double-strand breaks, oxidative lesions, or both (155). A number of recent investigations show 
that these damages are reflected as an increased micronucleus index in PBL, especially in the folate 
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and vitamin B12 deficiencies (156), which causes extensive incorporation of uracil into 
human DNA, leading to DNA breaks (157). 
The presence of an association between MN induction and cancer development is supported as 
well, by the high index of this biomarker shown in untreated cancer patients and in subjects affected 
by cancer-prone congenital diseases, e.g. Bloom syndrome or ataxia telangiectasia (158). 
The micronucleus test in exfoliated cells is a cost-effective, non-invasive method, through which 
the formation of MN in exfoliated cells from different organs, such as oral and nasal cavity, bladder, 
cervix, and oesophagus, is used as an endpoint to detect endogenous, lifestyle, occupational and 
environmental exposures to genotoxins as well as chemoprotection of various compounds in 
intervention studies (159). The non-invasive nature of this technique, where cultured cells are not 
needed for performing the MN assay, makes it an attractive candidate for biomonitoring of human 
populations or individuals (160).  
The analysis of micronuclei has gained increasing popularity as an in vitro genotoxicity test and a 
biomarker assay for human genotoxic exposure and effect. The main reasons for this development 
are obvious. In comparison with chromosomal aberrations (CA), the scoring of MN is simpler, 
requires shorter training and is less time-consuming. In principle, the MN assay can be expected to 
be more sensitive than the CA assay, because of the increased statistical power brought by the fact 
that the number of cells analysed can easily be increased to thousands when only a hundred or a 
few hundred cells are usually scored for CA (64). 
Recently some investigators have explored the benefits of performing this test in exfoliated 
urothelial cells in urine samples, as a biological marker of the genotoxic effects of bladder 
mutagenic/carcinogenic agents (161). The MN in exfoliated bladder cells results from genotoxic 
damage in basal cells of the urothelium. These cells have a high turnover rate; within 1-3 weeks 
they exfoliate along with any chromosomal damage to basal cells in their place of origin (162, 163). 
Because epithelial cells are derived from basal cells, recent genetic damage to the basal layer can 
be reflected in the presence of micronucleated (MNed) exfoliated cells (164). The mechanisms 
involved in the induction of MN in urothelial cells can be multiple. Exposure to genotoxic agents 
can explain part of the observed effects, but in certain cases, the effects occur by indirect 
mechanisms as occurs with arsenic exposure, which doesn’t have a direct effect on the DNA 
damage (165). Arsenic cytotoxicity action involves the metabolic generation of trivalent arsenicals 
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and their reaction with sulfhydryl groups within critical proteins in various cell types which leads 
to the biological response. In epithelial cells, the response is cell death with consequent 
regenerative proliferation and, ultimately, to an indirect induction of MN formation and cancer 
(166). Increased MN indices were detected in patients with chronic bladder inflammation as well 
(167). Additionally, MN formation was detected in the bladder cells of rats exposed to orto-
phenylphenol, a fungicide and antibacterial agent well known as a bladder tumour inducer in rats 
(168). 
It has been postulated that exfoliated mucosa cells have a high predictive value for the detection of 
carcinogenesis since the majority of human tumours are of epithelial origin (169). Cultured cells 
are not needed to perform an MN assay in exfoliated cells, and its non-invasive quality makes the 
assay an attractive candidate for biomonitoring human populations or individuals (160). 
In the 1980s, several exciting developments with regards to MN assays in humans emerged, which 
included the development of improved methods for scoring MNi in lymphocytes, buccal cells and 
erythrocytes. The cytokinesis-block micronucleus (CBMN) technique (as mentioned above), 
significantly improved the reliability of MN measurements in lymphocytes and led to its 
exponential adoption by numerous laboratories worldwide and has since been the most widely used 
method for studying micronuclei in human populations (170). In the cytokinesis-block method, 
enumeration of MNi is restricted to cells that are blocked from undergoing cytokinesis and which 
are consequently easily recognizable as large binucleate cells. The biological effects of 
Cytochalasin B (Cyt-B) were first described for lymphocytes by Carter (1967, 1972) who showed 
that Cyt-B at low concentrations (1 /~g/ml) inhibited cytoplasmic cleavage, apparently without 
blocking mitosis (130). But, does the cyt- B itself induces the micronucleus formation? Fenech and 
Morley (1985) have well investigated the use of Cyt-B as a method for accumulation of binucleated 
lymphocytes, and they claimed that under the concentration of 3.0 /~g/ml there was no evidence 
that Cyt-B itself causes an increase in micronucleus frequency (130). 
 As the time went by, it became increasingly evident that the possibility of measuring DNA damage 
in human populations worldwide was feasible and that there was, therefore, a need for an 
internationally coordinated effort to achieve this goal reliably and sustainably. So far, in 1997 The 
International Human Micronucleus (HUMN) Project was founded, with a mission to coordinate 
worldwide research efforts aimed at using MN assays to study DNA damage in human populations. 
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Their goals where to determine the main variables affecting micronucleus frequencies, 
establishment of the scoring criteria for this assay, set up a unified database with data collected 
from a big number of laboratories, all around the world, and possibly launch worldwide projects 
with the focus on different types of cells (like is the HUMNxl Project focused on MN in exfoliated 
cells) (170). Among the laboratories engaged in these projects was as well the Laboratory for Cell 
Biology of the Department of Biology, Faculty of Natural Sciences, University of Pristina (171), 
which has made a number of investigations using MN assay in different types of human and animal 
cells, contributing to the pooled analyses of the International Collaborative Project on 
Micronucleus Frequency in Human Populations (HUMN). 
Furthermore, micronucleus assay has gained application in biomonitoring of consequences from 
aquatic pollutants, performed in bivalves and fish (172). Field plants were used as well to be tested 
for cytogenetic changes for biomonitoring of radiation-induced genotoxicity of contaminants in 
natural environments (173).  
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2. HYPOTHESIS 
 
The index of MN in the epithelial exfoliated cells of urothelium in patients with bladder urothelial 
cell carcinoma increases with the gradus of the cell atypia. The increase of MN index of urothelial 
cells in patients with bladder urothelial cell carcinoma correlates with MN index in epithelial cells 
of buccal mucosa and peripheral blood lymphocytes of the same patients. 
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3. GENERAL AND SPECIFIC AIMS 
General aim: The aim of this study was to establish the relationship of the MN indices between the 
urothelial exfoliated cells, buccal mucosa exfoliated cells and peripheral blood lymphocytes in 
patients with bladder urothelial cell carcinoma. 
Specific aims: 
1. The assessment of the MN indices in epithelial exfoliated cells of urothelium and buccal 
mucosa, as well as in peripheral blood lymphocytes of healthy individuals, patients with 
low-grade urothelial cell carcinoma and patients with high-grade urothelial cell carcinoma. 
2. To analyse whether the MN indices in exfoliated urothelial and buccal cells, as well as in 
peripheral blood lymphocytes increase with the extent of the cell atypia in bladder cancer.  
3. To establish the coexistence of genomic instability in different cell types, located in distance 
from the primary lesion. 
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4. PATIENTS AND METHODS 
 
 
4.1. Patients 
 
The study sample consisted of 60 male participants. Subjects were divided into two groups as 
follows:  
1. Patient group – 40 patients diagnosed with bladder UCC  
2. Control group – 20 healthy men  
This study was conducted at the Urology Clinic and Institute of Pathology of the University 
Clinical Centre of Kosovo (UCCK) and Department of Biology, Faculty of Natural Sciences, 
University of Pristina “Hasan Pristina”. The investigated patients were collected prospectively 
from 2014 to 2017. The age range of the patient group was 37 to 78, while the controls were 
between 31 and 72 years of age.  
To be chosen for this study, each prospective subject was required to conform to the following 
criteria: non-smoker, non-alcohol consumer, and no history of chemo- or radiotherapy, as 
confounding factors (138, 145, 141, 174). Patients were first verbally briefed regarding the 
purposes of the study and were introduced to the sample collection procedure. Afterwards, patients 
were asked to provide information regarding their relevant personal information (name, age, 
occupation), family data (diseases with familiar predispositions) and medical data (present 
diseases, past diseases, habits). Informed written consent for sample collection was also obtained 
from each participant. The following three tissue samples were taken from all participants prior to 
the operation and diagnosis: urine, buccal mucosa exfoliated cells and blood.  
This research was approved by the Scientific Ethical Committee of UCCK (Nr. 566, date: 7 
February 2012). All methods were performed in accordance with the relevant guidelines and 
regulations. 
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4.2. Methods 
 
4.2.1. Micronucleus assay in urothelial exfoliated cells 
 
Midstream urine of the second or third void of the day was requested from each participant. The 
urine was collected in sterile urine containers and was processed within two hours. The volume of 
the voided urine ranged from 150–200 ml. 
Urine samples were transferred to centrifuge tubes and centrifuged at 2000 rpm for 15 min. The 
supernatant was then discarded without disturbing the pellets of urothelial cells. The pellets were 
washed twice with 0.9% NaCl and centrifuged. Cell suspensions were spread onto clean, preheated 
(40 °C) glass slides and allowed to air dry for 5–10 min. The slides were fixed in Carnoy I fixative 
(methanol: glacial acetic acid, 3:1) at 0 °C for 20 min and air dried. The slides were stained with 
May-Grunwald’s stain (0.25%) for 5 min, counterstained with Giemsa (4%) for 10 min and 
mounted in DPX. Four slides were prepared for each individual. Following the method of Reali et 
al. (175) and Fortin et al. (176), at least 1,000 urothelial cells per individual were analysed under a 
light microscope and confirmed by a second observer (Fig. 5: A, B, C). 
 
Figure 5. (A, B, C) Micronucleus in urothelial exfoliated cells (arrows). May Grunwald and 
Giemsa stain (magnification x400).  
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4.2.2. Micronucleus assay in buccal exfoliated cells 
 
 Buccal exfoliated cells were prepared and analysed after the method of Thomas et al. (177) and 
Tolbert et al. First, subjects removed unwanted debris from their oral cavities using a distilled water 
rinse. BEC were then obtained by rolling a cytobrush against the buccal mucosa ten times in a 
circular motion. Next, the heads of the brushes were individually placed into separate 30 ml yellow-
top containers, each of which contained a mixture of the following components: buccal cell buffer 
(0.01 M Tris-HCl; Sigma T-3253), 0.1 M EDTA tetrasodium salt (Sigma E5391), and 0.02 sodium 
chloride (Sigma S5886) at pH 7.0. The containers were then agitated to disperse cells. Cells were 
transferred into separate TV-10 centrifuge tubes and centrifuged for 10 min at 1500 rpm (MSE 
Mistral 2000). Slides containing two spots of cells were air dried for 10 min and then fixed in 
ethanol: acetic acid (3:1) for 10 min. Slides were then air dried for 10 min prior to staining with 
Giemsa (5%). At least four slides were prepared per individual, and 2,000 cells were analysed per 
case. The results are expressed as the number of micronucleated cells per 1,000 counted cells (‰). 
All the scoring criteria for observing these nuclear anomalies (Fig. 6: A, B, C) were taken from the 
corrected version of the Protocol of Thomas and Fenech (177).  
 
 
Figure 6. (A, B, C) Micronuclei in buccal exfoliated cells (arrows). Giemsa stain (magnification 
x400). 
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4.2.3. Cytokinesis-block-micronucleus cytome assay in peripheral blood 
lymphocytes 
 
Blood samples (5 ml) were collected via venipuncture into vacutainer blood tubes containing a 
lithium heparin anticoagulant (BD Plymouth. Pl6 7BP. UK). Whole heparinized blood (0.5 ml) 
was added to 5 ml of complete PB-Max Karyotyping medium for cell cultivation (Invitrogen, 
California, USA). All cultures were duplicated and incubated at 37 °C for up to 72 hours. 
Cytochalasin B (Sigma, St Louis, MO, USA) at a final concentration of 4 μg/mL was added 44 
hours after the incubation was initiated. The cells were centrifuged (Sigma, Germany) at 800 rpm 
for 10 min and treated with a hypotonic solution (0.075 M KCl). The cell suspension was then 
fixed in Carnoy I fixative (methanol: acetic acid, 3:1) three times and centrifuged (300 g/8 min) 
after each fixation. Finally, the centrifuged cells were resuspended in a small volume of fixative 
and spread onto specially prepared, cold, and lamp-dried slides. The slides were stained with 
Giemsa solution (5%). At least six slides per individual were prepared. Finally, using a light 
microscope, the MNi (Figure 7: A, B, C), NPBs (Figure 8: A, B) and NBUDs in PBL (Figure 9: A, 
B, C) were scored independently by two scorers for 1000 binucleated cells (500 per culture) 
according to the method of Fenech (95). 
 
 
Figure 7. (A, B, C) Micronucleus in binucleated peripheral blood lymphocytes (arrows). Giemsa 
stain (magnification x400). 
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Figure 8. (A, B) Nucleoplasmic bridges in binucleated peripheral blood lymphocytes (arrows). 
Giemsa stain (magnification x400). 
 
 
Figure 9. (A, B, C) Nuclear buds in binucleated peripheral lymphocytes (arrows). Giemsa stain 
(magnification x400). 
 
4.2.4. Scoring criteria for micronuclei, nucleoplasmic bridges and nuclear buds 
 
All the scoring criteria for observing these nuclear anomalies were taken from the corrected version 
of the Protocol of Michael Fenech, first published in 2007 (132). 
Criteria for selecting BN cells suitable for scoring MN, NPBs and NBUDs. The cytokinesis-
blocked BN cells that may be scored for MN, NPB and NBUD frequency should have the following 
characteristics:  
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 The cells should be binucleated.  
 The two nuclei in a binucleated cell should have intact nuclear membranes and be situated 
within the same cytoplasmic boundary.  
 The two nuclei in a binucleated cell should be approximately equal in size, staining pattern 
and staining intensity.  
 The two nuclei within a BN cell may be attached by a nucleoplasmic bridge, which is no 
wider than 1/4th of the nuclear diameter.  
 The two main nuclei in a BN cell may touch but ideally should not overlap each other. A 
cell with two overlapping nuclei can be scored only if the nuclear boundaries of each 
nucleus are distinguishable.  
The cytoplasmic boundary or membrane of a binucleated cell should be intact and clearly 
distinguishable from the cytoplasmic boundary of adjacent cells. The cell types that should not be 
scored for the frequency of MNi, NPBs and NBUDs frequency include mono- and multinucleated 
(with three or more nuclei) cells and cells that are necrotic or apoptotic.  
 
Criteria for scoring micronuclei. MNi are morphologically identical but smaller than nuclei. 
They also have the following characteristics:  
 The diameter of MNi in human lymphocytes usually varies between 1/16th and 1/3rd of the 
mean diameter of the main nuclei, which corresponds to 1/256th and 1/9th of the area of 
one of the main nuclei in a BN cell, respectively.  
 MNi are non-refractile and they can, therefore, be readily distinguished from artefact such 
as staining particles.  
 MNi are not linked or connected to the main nuclei.  
 MNi may touch but not overlap the main nuclei and the micronuclear boundary should be 
distinguishable from the nuclear boundary.  
 MNi usually have the same staining intensity as the main nuclei but occasionally staining 
may be more intense.  
In Table 1. are listed the mimickers of MN that can be misinterpreted during MN scoring 
procedure(178). 
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Table 1. Differential Diagnosis of Micronucleus 
Source of doubt  Differentiating points 
Nuclear debris  Background material  
 Smooth  
 Usually multiple 
Bacteria / 
bacterial colony 
 Single or just a clump of multiple round structures  
 Different texture than that of the nucleus  
 Present in the background 
Candida  Spores along with hyphae may be present  
 Located extra-cellular also  
 Multiple, same size, and monotonous staining 
Kerato-hyaline 
granule 
 Numerous  
 All over the cytoplasm  
 Polymorphic in size and texture, solid and monotonous 
Stain deposit  Polymorphic granules in the smear, generally over the cells – 
nucleus or cytoplasm or outside the cell.  
 Darker colour 
Platelet  Platelets have nebulous margin and woolly texture.  
 Lighter stain 
 
 
Criteria for scoring nucleoplasmic bridges. An NPB is a continuous DNA-containing structure 
linking the nuclei in a binucleated cell. NPBs originate from dicentric chromosomes (resulting from 
misrepaired DNA breaks or telomere end fusions) in which the centromeres are pulled to opposite 
poles during anaphase. They have the following characteristics:  
 The width of an NPB may vary considerably but usually does not exceed 1/4th of the 
diameter of the nuclei within the cell.  
 NPBs should also have the same staining characteristics as the main nuclei.  
 On rare occasions, more than one NPB may be observed within one binucleated cell.  
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 A binucleated cell with an NPB may contain one or more MNi.  
 BN cells with one or more NPBs and no MNi may also be observed.  
 
Criteria for scoring nuclear buds. An NBUD represents the mechanism by which a nucleus 
eliminates amplified DNA and DNA repair complexes. NBUDs have the following 
characteristics:  
 NBUDs are similar to MNi in appearance with the exception that they are connected with 
the nucleus via a bridge that can be slightly narrower than the diameter of the bud or by a 
much thinner bridge depending on the stage of the extrusion process.  
 NBUDs, usually, have the same staining intensity as MNi.  
 Occasionally, NBUDs may appear to be located within a vacuole adjacent to the nucleus.  
A small protrusion of nuclear material from the nucleus without an obvious constriction between 
the nucleus and the protruding nuclear material should not be classified as a nuclear bud. 
 
4.2.4. Statistical analysis  
 
Since the study variables (the indices of MN in UEC, BEC and PBL as well as NBUD and NPB in 
PBL) did not follow the normal distribution (tested by Kolmogorov-Smirnov test), non-parametric 
methods were used. Mann-Whitney U test was applied for comparison of two independent groups. 
Correlation analysis between study variables was calculated as Spearman’s rank correlation 
coefficients. All the analyses were performed by Statistica (data analysis software system), version 
13 (TIBCO Software Inc. (2018). The results were expressed as the mean ± standard deviation 
(SD). A value of p < 0.05 was considered statistically significant. 
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5. RESULTS 
 
The characteristics of the study population are shown in table 2. The MN indices in UEC, BEC and 
PBL in the patient group (n=40) were about 17 times higher, 3 times higher, and 4 times higher, 
respectively, than the MN indices in UEC, BEC, and PBL in the control group (n=20) (Figure 10: 
A, B, C). Furthermore, the NPB and NBUD indices in PBL in the patient group were 10 times 
higher and 12 times higher, respectively, than in the control group (Figure 10: D, E).  
 
Table 2. Baseline characteristics of bladder urothelial carcinoma patients and controls 
COVARIATES CASES (%) CONTROLS 
Number 40 20 
NMIUC 16 (40%) - 
MIUC 24 (60%) - 
Age range 37-78yrs 31-72yrs 
Smoking status Non-smokers Non-smokers 
T stage  - 
Ta 15 (37%) - 
T1 14 (35%) - 
T2 8 (20%) - 
T3 1 (2.5%) - 
T4 2 (5%) - 
Tis - - 
Tx - - 
Grading (WHO 
2004) * 
 - 
Low grade 20 (50%) - 
High grade 20 (50%) - 
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Recurrence  - 
Recurrent 12 (30%) - 
Non-recurrent 28 (70%) - 
Abbreviations: NMIUC – Non-muscle invasive urothelial 
carcinoma; MIUC- Muscle invasive urothelial carcinoma. 
*For reference see: Eble JN et al. Pathology and Genetics of 
Tumors of the urinary system and male genital organs, (2004). 
 
 
Since study variables did not follow a normal distribution (tested by Kolmogorov-Smirnov test), 
non-parametric tests were employed to verify differences among groups: Man-Whitney U test was 
applied to see the differences between two independent groups, and Spearman’s rank correlation 
was applied to show the relationship between study variables. 
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Figure 10. Box plots showing MN indices in: (a) urothelial exfoliated cells (UEC), (b) buccal exfoliated cells (BEC) and (c) peripheral 
blood lymphocytes (PBL), as well as (d) nucleoplasmic bridges (NPBs) and (e) nuclear buds (NBUDs) indices in PBL in the control 
group, low grade and high grade patient groups. 
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According to Man Whitney U test, statistically significant differences were found in all study 
variables when the patient group (n=40) was compared to the control group (n=20) (p< 0.001; 
Table 3). 
 
Table 3. Mann-Whitney U test (with continuity corrections) between UCC patients (n=40) and 
controls (n=20) 
 Mean 
rank 
UCC 
Mean 
rank 
control 
U z p value z adjusted p value Two-sided 
exact p value 
MN in UEC 40.33 10.85 7.0 6.155 <0.001 6.202 <0.001 <0.001*** 
MN in BEC 38.04 15.43 98.5 4.720 <0.001 4.739 <0.001 <0.001*** 
MN in PBL 39.41 12.68 43.5 5.583 <0.001 5.638 <0.001 <0.001*** 
NPBs in 
PBL 
36.66 18.18 153.5 3.858 <0.001 4.105 <0.001 <0.001*** 
NBUDs in 
PBL 
37.50 16.50 120.0 4.383 <0.001 4.594 <0.001 <0.001*** 
*** p<0.001 
UCC- urothelial cell carcinoma; MN-micronucleus; UEC-urothelial exfoliated cells; BEC- buccal exfoliated 
cells; PBL- peripheral blood lymphocytes; NPBs- nucleoplasmic bridges; NBUDs- nuclear buds. 
 
 
Spearman’s rank correlation showed no significant correlation between study variables in the 
control group (Table 4). However, in the patient’s group (Table 4), Spearman’s correlation showed: 
moderate positive correlation between the MN indices in UEC and BEC (rho=0.427, p=0.006, 
Figure 11); between the MN indices in BEC and PBL (rho=0.382, p=0.015, Figure 12), and 
between the MN index in PBL and the NPB index in PBL (rho=0.327, p=0.040, Figure 13). 
Furthermore, a strong positive correlation was found between the indices of NPBs and NBUDs in 
PBL (rho=0.701 and p<0.001, Figure 14). There was a positive correlation between the MN and 
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NBUD indices in PBL, but it did not reach the level of statistical significance (rho=0.271, p=0.091, 
Figure 15) (Table 4). 
As it can be seen in the patient group statistically significant positive correlations were found 
pairwise between all variables except between MN in PBL with NBUD (rho=0.271, p=0.091, 
Figure 15) and MN in UEC and MN in PBL (rho=0.197, p=0.224, Figure 16), which might also be 
statistically significant on a larger sample of patients. 
 
Table 4. Spearman’s correlation of the MN indices in UEC, BEC and PBL and the NPB and NBUD 
indices in PBL in the control group, all cases group, the NMIUC and MIUC subgroups and the low 
grade and high-grade subgroups 
  MN in 
UEC: MN 
in BEC 
MN in 
UEC: MN 
in PBL 
MN in 
BEC: MN 
in PBL 
MN in PBL: 
NPB 
MN in PBL: 
NBUD 
NPB: NBUD 
Control group 
(n=20) 
rho 
p 
-0.091 
0.702 
0.082 
0.732 
0.264 
0.261 
0.049 
0.831 
0.049 
0.837 
-0175 
0.459 
Patients (n=40) rho 
p 
0.427** 
0.006 
0.197 
0.224 
0.382* 
0.015 
0.327* 
0.040 
0.271 
0.091 
0.701*** 
<0.001 
NMIUC (n=16) rho 
p 
0.421 
0.104 
0.018 
0.947 
0.245 
0.361 
-0.093 
0.731 
-0.194 
0.472 
0.861*** 
<0.001 
MIUC (n=24) rho 
p 
0.343 
0.100 
0.141 
0.511 
0.478* 
0.018 
0.552** 
0.005 
0.450* 
0.027 
0.622** 
0.001 
Low grade UCC 
(n=20) 
rho 
p 
0.468* 
0.038 
0.277 
0.236 
0.328 
0.158 
0.039 
0.871 
0.055 
0.818 
0.579** 
0.007 
High grade 
UCC 
(n=20) 
rho 
p 
0.213 
0.367 
-0.163 
0.492 
0.339 
0.144 
0.185 
0.435 
-0.180 
0.447 
0.710*** 
<0.001 
*statistically significant positive correlation p<0.05 
** statistically significant positive correlation p<0.01 
*** statistically significant positive correlation p<0.001 
UCC- urothelial cell carcinoma; NMIUC-non-muscle invasive carcinoma; MIUC- muscle invasive carcinoma; 
MN-micronucleus; UEC-urothelial exfoliated cells; BEC- buccal exfoliated cells; PBL- peripheral blood 
lymphocytes; NPBs- nucleoplasmic bridges; NBUDs- nuclear buds. 
 
53 
 
 
Figure 11. Spearman’s rank correlation between MN indices in UEC and BEC in patient group 
(n=40) and control group (n=20) (arcsin transformed data). 
 
 
 
Figure 12. Spearman’s rank correlation between MN indices in UEC and BEC in patient group 
(n=40) and control group (n=20) (arcsin transformed data). 
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Figure 13. Spearman’s rank correlation between MN and NPBs indices in PBL in patient group 
(n=40) and control group (n=20) (arcsin transformed data). 
 
 
Figure 14. Spearman’s rank correlation between NPBs and NBUDs indices in PBL in patient 
group (n=40) and control group (n=20) (arcsin transformed data). 
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Figure 15. Spearman’s rank correlation between MN and NBUDs indices in PBL in patient 
group (n=40) and control group (n=20) (arcsin transformed data). 
 
 
Figure 16. Spearman’s rank correlation between MN indices in UEC and PBL in patient group 
(n=40) and control group (n=20) (arcsin transformed data). 
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Statistically significant differences were found in all study variables when patients, stratified by 
tumour grade into the low grade (n=20) and high grade (n=20) subgroups, were compared between 
one another (p<0.05; Table 5).  
 
Table 5. Mann-Whitney U test (with continuity corrections) between UCC low grade (n=20) and 
UCC high grade (n=20) patients 
 Mean rank  
Low grade 
Mean rank 
High grade 
 
U 
 
z 
 
p value 
z 
adjusted 
 
p value 
Two-sided exact p 
value 
MN in UEC 16.88 24.13 127.5 -1.948 0.051 -1.954 0.051 0.049* 
MN in BEC 15.65 25.35 103.0 -2.610 0.009 -2.620 0.009 0.008** 
MN in PBL 13.98 27.03 69.5 -3.517 0.000 -3.554 0.000 <0.001*** 
NPBs in PBL 14.58 26.43 81.5 -3.192 0.001 -3.258 0.001 0.001** 
NBUDs in 
PBL 
15.00 26.00 90.0 -2.962 0.003 -3.010 0.003 0.002** 
* p<0.05; ** p<0.01; *** p<0.001 
UCC- urothelial cell carcinoma; MN-micronucleus; UEC-urothelial exfoliated cells; BEC- buccal exfoliated 
cells; PBL- peripheral blood lymphocytes; NPBs- nucleoplasmic bridges; NBUDs- nuclear buds. 
 
 
When patients were stratified by tumour muscle invasion into non-muscle invasive urothelial 
carcinoma (NMIUC, n=16) and muscle-invasive urothelial carcinoma (MIUC, n=24), and 
compared statistically significant difference was found only in MN indices in UEC (p=0.044 or 
p<0.05), whereas MN indices in BEC, PBL, as well as NPB and NBUD indices in PBL,  did not 
differ between NMIUC and MIUC subgroup (p>0.05 in all cases, Table 6).  
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Table 6. Mann-Whitney U test (with continuity corrections) between subgroups stratified 
according to tumour muscle invasion: MIUC (n=24) and NMIUC (n=16) 
 Mean rank 
MIUC 
Mean rank 
NMIUC 
 
U 
 
z 
 
p value 
 
z 
adjusted 
 
p value 
Two-sided 
exact p value 
MN in UEC 23.52 15.97 119.5 1.988 0.047 1.994 0.046 0.044* 
MN in BEC 22.15 18.03 152.5 1.077 0.282 1.081 0.280 0.279 
MN in PBL 22.44 17.59 145.5 1.270 0.204 1.283 0.199 0.202 
NPBs in PBL 21.42 19.13 170.0 0.594 0.553 0.606 0.545 0.557 
NBUDs in PBL 22.17 18.00 152.0 1.091 0.275 1.108 0.268 0.279 
* p<0.05 
NMIUC-non-muscle invasive carcinoma; MIUC- muscle invasive carcinoma; MN-micronucleus; UEC-
urothelial exfoliated cells; BEC- buccal exfoliated cells; PBL- peripheral blood lymphocytes; NPBs- 
nucleoplasmic bridges; NBUDs- nuclear buds. 
 
Spearman’s rank correlation coefficients were calculated for two subgroups formed according to 
muscle invasiveness i.e. within subgroups MIUC (n=24) and NMIUC (n=16). Within both groups 
a very strong positive correlations were found between NPBs and NBUDs (rho=0.622, p=0.001 
and rho=0.861, p<0.001 for MIUC and NMIUC subgroup, respectively) (Table 4). In the same 
time not any other pair of variables showed correlation in NMIUC subgroup while statistically 
significant correlation coefficients were found in MIUC subgroup between MN in BEC and MN 
in PBL, MN in PBL and NPBs as well as MN in PBL and NBUDs (p<0.05 in all three cases) (Table 
4). According to the tumour grade, in the low-grade subgroup a positive correlation was found 
between the MN index in UEC and the MN index in BEC (rho=0.468, p<0.038), as well as between 
the NPBs and NBUDs indices within the low grade and high-grade subgroups (rho=0.579, 
p<0.007; rho=0.710, p<0.000, respectively; Table 4). 
Finally, when MN in UEC, BEC and PBL, as well as NPBs and NBUDs, were correlated with the 
tumour stage and tumour recurrence, we found that among all of these variables, only the MN 
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index in PBL showed a positive correlation with the tumour stage but it did not reach the level of 
statistical significance (rho=0.276, p=0.085 or 0.05<p<0.10) (Table 7). 
 
Table 7. Correlation between the index of MN in UEC, BEC, PBL as well as NPBs and NBUDs with 
tumour recurrence and tumour stage 
 
Frequency 
Recurrence Tumour stage 
rho 
 
p-value Rho p-value 
MN in UEC -0.101 0.536 0.248 0.122 
MN in BEC -0.140 0.389 0.61 0.706 
MN in PBL -0.031 0.848 0.276 0.085 
NPBs -0.265 0.098 0.234 0.147 
NBUDs -0.128 0.432 0.180 0.267 
Statistically significant correlation at p<0.05   
Rho-Sperman’s Rank Correlation                                                                                                      
MN-micronucleus; UEC-urothelial exfoliated cells; BEC- buccal exfoliated cells; PBL- peripheral blood 
lymphocytes; NPBs- nucleoplasmic bridges; NBUDs- nuclear buds 
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6. DISCUSSION  
 
It is well established that cancer has a genetic basis. Cancer development is a multistep process 
that involves the progressive accumulation of DNA damage, leading to the activation of oncogenes 
and to the loss of tumour suppressor functions, which in turn, result in changes in cell function and 
in the transformation of cells into the malignant cell (179). The search for cytogenetic biomarkers 
for the identification of groups and individuals who are at high risk of developing cancer is an 
important initiative in public health. By identifying and validating the markers for cancer risk, the 
global community can improve disease outcomes and increase the frequency of early diagnoses. In 
this research project, we used the MN assay in UEC and BEC and the CBMN cytome assay in PBL 
to evaluate genomic instability in bladder UCC patients. To the best of our knowledge, this is the 
first study performed on all three cell types of first-diagnosed non-smoker bladder cancer patients. 
Two previous studies performed MN assays in three types of cells (UEC, BEC and PBL) to 
evaluate those cells in individuals exposed to arsenic exposure (143) and cigarette consumption 
(148), but none in cancer patients. These studies reported a slight increase in the prevalence of 
micronuclei in lymphocytes compared to exfoliated epithelial cells. However, those results may be 
confounded by the discrepancy in the turnover rates of these two cell types, with lymphocytes 
exhibiting a longer lifespan than epithelial cells (180). In our observation, different MN means 
were found among the three cell types in patients with developed UCC. Specifically, exfoliated 
cells had a greater prevalence of MN than PBL. Recently, there has been a growing emphasis on 
the value of utilizing the MN assay in exfoliated cells as a method for the early detection and/or 
monitoring of cancer patients, as well as the evaluation of different exposures, due to the method’s 
cost-effectiveness and non-invasiveness  (170, 181). 
Given that epithelial cells are highly proliferative and that they represent the origin of more than 
90% of all human cancers (182), it is evident that epithelial cells represent a reasonable alternative 
to PBL for biomonitoring studies, thus the use of the micronucleus assay has been extended to cells 
other than lymphocytes, basically exfoliated epithelial cells. Approximately more than 200 studies 
with epithelial cells have been published in the last 30 years and apart from cells of the oral mucosa, 
cells from other organs, such as nasal mucosa, cervix, bladder, oesophagus and bronchi, were also 
used (183). MN frequency in PBL is considered a general biomarker more than a specific one of a 
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particular type of cancer. Furthermore, while CBMN in PBL requires cell culturing, isolation of 
UEC can be accomplished via urine sample centrifugation alone. In the approximately thirty years 
since epithelial cells from human urine were first used for MN analyses, approximately 56 studies 
have been published (181), most of which were performed to predict the risk of UCC based on the 
presence of MN-promoting genotoxic metabolites in urothelial cells.  
Our results show that the MN index in UEC is significantly higher in patients with UCC than in 
individuals in the control group as well as between subgroups according to tumour grade and the 
tumour muscle invasion. Several confounding factors (lifestyle habits (smoking, alcohol, etc.), age, 
exposure to mutagen agents) may modulate MN formation and frequency (184), but the 
abovementioned association in our study was independent of these factors, suggesting that 
endogenous factors are likely to be the most relevant causative factors that contribute to DNA 
damage in UCC. Endogenous sources of DNA damage, in particular oxidative DNA damage, may 
contribute to genomic instability and to a mutator phenotype in some tumours (185). This result 
agrees with a previous study that phenotypically profiled urothelial cells in unexposed patients with 
a prior history of UCC (186). They claimed to have found genetic unstable cells in the normal 
appearing urothelium of resected patients. Similarly, the results of a separate previous study 
indicated that the MN index in urothelial cells from bladder washings of patients with a history of 
UCC was higher than that of the control group (47). Furthermore, in a retrospective study of urine 
samples, slides that had been identified as atypical urothelial cells and subsequently diagnosed as 
UCC positive were found to be positive for MN. By contrast, slides from the control group did not 
contain MN (187).  
There is a lack of literature in performing MN assay in UEC of UCC patients. Only a few studies 
have been carried out with bladder cancer patients until now, and all of them used low numbers of 
patients. The most recent one, results to be the largest, using bladder washings from 383, from 
them 77 patients were negative in their first cystoscopy, and were considered as a reference group; 
79 were positive and were classified as patients with tumour; and 227 with previous bladder cancer 
submitted to follow-up monitoring were negative and classified as BC patients without tumour 
(165). Their findings are in line with our results, pointing out the presence of genomic instability 
in patients with UCC, their positive correlation with tumour grade, but not with tumour recurrences. 
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In contrast, in a recent association study elevated MN frequencies were observed in patients with 
recurrent neoplasia, compared with patients with no-recurrent neoplasia, supporting MN as 
appropriated tool to detect individuals with increased risks (47). 
Based on our findings and those of aforementioned studies, it is obvious that subjects who are at 
high risk for UCC, who have UCC, or who have a history of UCC harbour and accumulate 
genetically unstable cells in the bladder urothelium, which may represent early precursors of new 
UCC or subclones from previous UCC (47), and that these changes can be readily detected via an 
MN assay performed on urine. 
Use of the MN assay in buccal cells is a well-established and standardized method (177) that has 
been widely used in biomonitoring processes. In the present study, observation of the MN index in 
buccal mucosa cells revealed significantly higher levels of genomic instability in patients with 
UCC than in controls, similar to what was found in PBL and UEC. The MN index in BEC was 
found to have a statistically significant positive correlation with UEC and PBL in the patient group 
(p < 0.006, p < 0.015, respectively; Table 4). Our findings are in line with Feki-Tounzi et al (188), 
who observed a higher MN index in BEC of patients with UCC than in controls. While there is a 
lack of literature studying the MN index in BEC among bladder cancer patients, a number of papers 
have explored the MN index in BEC among patients with head and neck cancer (189), oral cancer 
(190), breast cancer, and uterine cancer (191), as well as among those with cervical pre-cancer and 
cancer (192, 193). These studies are consistent with our findings, showing that the MN index in 
PBL is significantly reflected by the MN index in oral exfoliated epithelial cells, as surrogated 
cells, even in precancerous lesions. 
The CBMN assay is a genotoxicity assay that provides information on a variety of endpoints that 
reflect chromosomal breakage and rearrangements as well as gene amplification (194). 
Measurement of the MN index in PBL is extensively used in molecular epidemiology and 
cytogenetics to evaluate the presence and extent of chromosomal damage in human populations 
exposed to genotoxic agents (134). Most lymphocytes are short-lived, with an average life span of 
a week to a few months, but a few live for years, providing a pool of long-lived T and B cells, that 
recirculate through the secondary lymphoid tissues (195). PBL circulate and accumulate DNA 
damage over their lifespans due to their close contact with different tissue microenvironments or 
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tumour-derived substances. Thus, chromosomal aberrations in PBL are considered to be valuable 
biomarkers of genomic instability and predictors of cancer risk (196). 
The association between the MN index in PBL and cancer risk is supported by a number of 
observations (63, 197).  The HUMN International Collaborative Project assembled a large 
international cohort of subjects, whose lymphocytes had been screened for MN frequency in a 
period of time from 20 years. They gathered data from about 20 laboratories, and of about 6718 
individuals. They found that subjects in medium and high tertile had a higher risk for cancer, 
relative to the low tertile. This study suggested that increased MN formation is associated with 
early events in carcinogenesis (63).  
In the present study, the MN index in PBL in UCC patients was significantly higher than that in 
healthy subjects, confirming the results of Pardini et al., who found a higher index of MN in PBL 
and an increased index of NPBs and NBUDs in patients than in controls. Moreover, they found a 
statistically significant difference between non-muscle invasive UCC patients with controls but not 
between controls and muscle invasive UCC patients nor among tumour grades and recurrence 
(197). In contrast, the present study found statistically significant differences in the MN, NPB and 
NBUD indices in PBL when comparing the two subgroups (according to tumour grade) between 
one another, but not when these variables were compared between subgroups according to tumour 
muscle invasion. 
Investigations of genomic instability on primary tumour and/or tumour precursors cells, recently 
have been a field of interest for researchers, which used MN assay to show different levels of 
genomic instability in different grades of preneoplastic and neoplastic lesions. Our results show a 
grade-dependent relationship with the levels of MN formation, which is equivalent with the data 
in the literature. Similar results were found, for example: in breast cancer cells provided from fine 
needle aspiration (FNA) the MN index was significantly correlated with tumour grade (198), (199); 
in cervical dysplasia was revealed a statistically significant difference between different grades of 
dysplasia (135), as well as between invasive squamous cell carcinoma (SCC) and high grade 
squamous intraepithelial lesions (HSIL) compared with low grade squamous intraepithelial lesions 
(LSIL) and control group (200, 201); similar results were shown also in oral squamous cell 
carcinoma where the level of genomic instability correlated positively with the tumour 
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histopathological grade (182, 202). These investigations are in line with our finding, pointing out 
the positive correlation of the MN indices with different tumour grades.  
An increased MN frequency may be considered to be a biomarker of chromosome loss and/or 
breakage, whereas other anomalies, such as NBUDs, are biomarkers of gene amplification and/or 
the removal of unresolved DNA repair complexes, and NPBs are biomarkers of DNA misrepair 
and/or telomere end-fusions (203). The increased nuclear anomalies in PBL and BEC indicate that 
the induction of chromosomal damage employs similar mechanisms in different tissues and that 
the levels of DNA damage measured in surrogate tissues may reflect those present in cancer-prone 
tissues (203, 204). It is estimated that each human cell is subjected to 70,000 lesions per day (205) 
as a result of exogenous and endogenous factors. Because the majority of DNA repair pathways 
are eliminated, these important pathways can be inactivated due to the action of such factors, 
leading to genomic instability, which in turn causes an increase in the gene mutation rate at other 
genomic sites and leads to cellular transformations (206). Furthermore, abnormal active tumour 
substances leak from cell membranes and may enter blood circulation and interact with other 
tissues, probably destabilizing their genome.  
The increased MN index in the PBL and BEC of UCC cases compared with that of controls could 
be interpreted as an altered status of the DNA damage repair system or to reflect an unknown past 
exposure (197). Although our patients were non-smokers and non-alcohol consumers and they 
denied any professional exposure, we cannot rule out other unknown confounding factors that 
might have an impact on their genomic instability. There are contradictory endpoints after a number 
of investigations performed in NATO soldiers who served in the Kosovo war regarding the effect 
of the weapons of war, especially those with depleted uranium, on cancer risk elevation. A 
Norwegian investigation showed a 5-fold increase in the incidence of bladder cancer among 
soldiers who served in Kosovo compared with the general Norwegian population (207, 208). Other 
studies show an increased number of cancer and MN frequencies in the Bosnian population in 
regions exposed to depleted uranium during the Bosnian war (209, 210). In Eastern Croatia was 
reported an 3.5 times increased incidence rate for testicular tumours in Croatians from the pre-war 
period to the post-war period (211). In Kosovo, there is no investigation that shows the level of 
contamination with such agents, so this hypothesis remains at the level of speculation and should 
be investigated in the future.  
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Chromosomal instability correlates with tumour metastasis, but it remains unclear whether it is 
merely a bystander or a driver of metastatic progression (212). In our study, the nonsignificant 
differences in most study variables between subgroups (NMIUC and MIUC) reveal that the 
invasive feature of the tumour is likely not directly linked with the level of CIN. It is known that 
higher tumour grades harbour higher levels of CIN, but it is also known that low-grade and high-
grade UCC can both be invasive. Therefore, there may be other mechanisms that generate invasive 
clones within UCC (213, 214) in a persistent established state of CIN. 
Our data indicate that in UCC, a systemic genomic destabilization occurs and that it can be easily 
detected using the MN assay in UEC, BEC and PBL, which means that these cells reflect the CIN 
in the UCC state. Bladder cancer continues to be challenging to detect and treat. Early diagnosis, 
prior to muscle invasion, can greatly impact the clinical outcome, whether measured by disease-
specific survival, morbidity, or quality-of-life variables (215). While cystoscopy and cytology are 
established standards, the UroVysion™ FISH test is a new but expensive and technically 
demanding approach that focuses on chromosomal aneuploidy using fluorescent in situ 
hybridization (FISH) (216) and is mainly used as a surveillance test for NMIUC patients. It is well 
recognized that high pre-diagnostic levels of MN are associated with an elevated risk for cancer 
development. It is also known that tetrasomy of chromosomes 3, 7 and 17 and loss of 9p21 can be 
detected in urine samples 1–3 years before diagnosis (217) . Although more extensive studies are 
needed, we recommend the following practical approach for cancer screening: combined testing 
for bladder cancer, in which the MN assay in UEC might serve as a triage-test for the identification 
of people who are at high risk for bladder cancer development so that they can be referred for 
UroVysion™ FISH testing.  
It is known that cost concerns are a strong determinant of testing, so it can contribute to low testing 
in at risk for cancer population. Hence, identification of additional tests that would enhance the 
detection rate and will lower the cost, can be of high importance for the health system’s cancer 
screening programs. The identification of biomarkers of bladder cancer susceptibility in easily 
accessible tissues, like UEC, may allow targeting of screening efforts in the way of improving the 
bladder cancer prognosis. In this regard, standardized MN assay in UEC could be considered as a 
promising biomarker of bladder cancer susceptibility. Its cost-effectiveness might expand access 
to screening for bladder cancer early detection, especially in low- and middle-income countries, 
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what might be probably reflected in the patient treatment, in setting of better clinical outcomes due 
to early detection, and lower costs in cancer treatment. This method could reduce the number of 
unnecessary tests with UroVysion™ FISH.  
Strengths and limitations. This study used a very homogenous sample. The inclusion criteria for 
eligibility, especially the non-smoking status, made the sample collection phase to be a long and 
challenging process, that resulted in a relatively small sample size. The lack of the literature for 
MN test done in bladder cancer patients was another problem in the process of writing. Despite 
this, the study is valuable as an explorative one, significantly pointing to the presence of a systemic 
genomic instability due to bladder cancer disease. Although, further studies are needed to set up or 
to standardize MN frequencies in UEC, BEC, PBL as well as NPBs and NBUDs in PBL, to be 
routinely included as predictive diagnostic criteria for bladder cancer early diagnosis, and cancer 
surveillance. 
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7. CONCLUSIONS  
 
Based on the study outcomes, regarding the micronucleus indices in urothelial exfoliated cells 
(UEC), buccal exfoliated cells (BEC) and peripheral blood lymphocytes (PBL), as well as 
nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) in peripheral blood lymphocytes 
between urothelial cell carcinoma (UCC) patient groups (stratified according to tumour grade and 
tumour muscle invasion), it can be concluded that: 
1. The increased genomic instability in patients with urothelial cell carcinoma is 
manifested with higher MN indices in UEC, BEC and PBL, as well as NPB and 
NBUD indices in PBL. 
2. MN index in UEC is significantly higher in high grade UCC and muscle invasive 
urothelial carcinoma (MIUC) compared to opposite subgroups. 
3. Our results show a grade-dependent relationship with the study variables: all of them 
showed statistically significant differences between low grade UCC and high grade 
UCC subgroups (p<0.05 in all cases) 
4. The study variables did not show any statistically significant difference between 
subgroups according to tumour muscle invasion, except for MN in UEC (p<0.04). 
5. Statistically positive correlation is found between MN indices in UEC and BEC and 
between BEC and PBL in patient group. 
6. MN indices in UEC and PBL are significantly higher in the patient group than in the 
control group, but they did not show any positive correlation between them.  
7. In PBL positive correlations are found between indices of MN and NPBs and between 
indices of NPBs and NBUDs. 
In conclusion, our data show that genomic instability can be detected through the MN assay in 
target cells (UEC) as well as in surrogate cells (BEC and PBL). The extent of DNA damage varies 
among the three cell types, but their simultaneous appearance suggests that similar mechanisms 
can cause a systemic genomic instability in different types of cells during carcinogenesis. The 
positive correlation between MN indices in PBL and BEC shows that the genomic instability due 
to bladder cancer disease is a generalized state, and it can equally be detected in both surrogated 
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cells. The statistically nonsignificant correlation between MN in UEC and MN in PBL can be 
attributed to the relatively small sample size. 
Although further studies are needed for standardization, our findings support the data in the field 
that indicate that the MN index in exfoliated cells (especially in UEC) may be a potential biomarker 
for the early detection of bladder cancer and for patient surveillance. The MN index in exfoliated 
cells might also be able to be used as an additional triage test prior to the UroVysion™ FISH test. 
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8. ABSTRACT IN ENGLISH 
 
Microncronucleus index in epithelial exfoliated cells of urothelium and buccal mucosa, and 
peripheral blood lymphocytes of patients with papillary urothelial carcinoma, Arjeta 
Podrimaj-Bytyqi, 2019 
 
Introduction: Bladder urothelial cell carcinoma (UCC) is an increasingly prevalent cancer 
worldwide, and thus, gaining a better understanding of its identifiable risk factors is a global 
priority.  
Aim: This study addressed this public health need with the understanding that cancer-initiating 
events, such as chromosome breakage, loss and rearrangement, can be reasonably used as 
biomarkers to evaluate an individual’s cancer risk.  
Methods: Overall, forty bladder cancer patients and twenty controls were evaluated for genomic 
instability. To the best of the investigators’ knowledge, this is the first study to perform 
micronucleus (MN) assays simultaneously in urothelial exfoliated cells (UEC), buccal exfoliated 
cells (BEC), and peripheral blood lymphocytes (PBL) in first-diagnosed, non-smoker bladder UCC 
patients. Additionally, the frequency of nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) 
in PBL was evaluated.  
Results: The MN indices in UEC, BEC, and PBL, as well as the indices of NPBs and NBUDs, 
were significantly higher in patients than in controls. Different levels of genomic instability were 
found also in relation to tumour grade and tumour muscle invasion. 
Conclusions: MN assays, particularly in UEC, may be used to identify individuals who are at high 
risk of developing UCC, as single or as additional triage test to UroVysion FISH test. Our results 
further validate the efficacy of such biomarkers as predictors of genomic instability. 
Keywords: micronucleus assay, urothelial cell carcinoma, buccal exfoliated cells, urothelial 
exfoliated cells, peripheral blood lymphocytes. 
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9. SAŽETAK (ABSTRACT IN CROATIAN) 
 
Uvod: Karcinom urotela mokraćnog mjehura sve je učestaliji oblik karcinoma u svijetu te je stoga 
bolje razumijevanje njegovih prepoznatljivih čimbenika rizika globalni prioritet. 
Cilj rada: Ovo istraživanje se bavi tom javnozdravstvenom potrebom da se događaji koji iniciraju 
rak, kao što je lom, gubitak i preraspodjela kromosoma, racionalno iskoriste kao biomarkeri za 
procjenu rizika od karcinoma urotela.  
Ispitanici i metode: Četrdeset bolesnika s de novo karcinomom urotela mokraćnog mjehura i 
dvadeset kontrolnih ispitanika analizirano je na genomsku nestabilnost. Prema dostupnim 
saznanjima istraživača, ovo je prva studija takve vrste koja je provela istodobno ispitivanje 
mikronukleusa (MN) na izljuštenim urotelnim stanicama, izljuštenim epitelnim stanicama sluznice 
usne šupljine i limfocitima periferne krvi bolesnika s de novo dijagnosticiranim karcinomom 
urotela mokraćnog mjehura. Osim toga, procijenjena je i učestalost nukleoplazmatskih mostova 
(NPB) i nuklearnih pupoljaka (NBUD) u limfocitima periferne krvi bolesnika i kontrolnih 
ispitanika. 
Rezultati: Učestalost MN u izljuštenim urotelnim stanicama, izljuštenim epitelnim stanicama 
sluznice usne šupljine i  limfocitima periferne krvi, kao i učestalost NPB i NBUD  u limfocitima 
periferne krvi bila je značajno viša u bolesnika s karcinomom urotela nego li u kontrolnih 
ispitanika. Dodatno je utvrđen i stupanj genomske nestabilnosti u odnosu na stupanj tumora i 
invaziju tumorskih mišića: MN indeks bio je značajno viši u karcinomu visokoga stupnju i u 
invazivnom karcinomu nego u neinvazivnim podskupinama.  
Zaključak: Testiranje mikronukleusa, a posebice na izljuštenim urotelnim stanicama, može se 
koristiti za otkrivanje pojedinaca koji se nalaze pod visokim rizikom za razvoj karcinoma urotela, 
bilo kao pojedinačni test ili kao dodatni trijažni test za UroVysion FISH test. Dobiveni rezultati 
dodatno potvrđuju učinkovitost analiziranih biomarkera kao prediktora genomske nestabilnosti. 
 
Ključne riječi: mikronukleusni test, karcinom urotela, izljuštene epitelne stanice sluznice usne 
šupljine, izljuštene urotelne stanice, limfociti periferne krvi. 
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